



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification<sup>5</sup> :</b> <b>C07K 5/06, 5/08, A61K 37/64</b> <b>C07K 5/02</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 91/15507</b> <b>(43) International Publication Date:</b> 17 October 1991 (17.10.91)
<b>(21) International Application Number:</b> PCT/GB91/00538 <b>(22) International Filing Date:</b> 5 April 1991 (05.04.91)  <b>(30) Priority data:</b> 9008078.9 10 April 1990 (10.04.90) GB  <b>(71) Applicant (for all designated States except US):</b> BEECHAM GROUP PLC [GB/GB]; SB House, Great West Road, Brentford, Middlesex TW8 9BD (GB).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> MARKWELL, Roger, Edward [GB/GB]; WARD, Robert, William [GB/GB]; RATCLIFFE, Steven, John [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB).		<b>(74) Agent:</b> RUSSELL, Brian, John; SmithKline Beecham, Corporate Patents, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB).  <b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent), US.  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> PHOSPHONOPEPTIDES WITH COLLAGENASE INHIBITING ACTIVITY  <div style="text-align: center;"> <p style="text-align: right;">(I)</p> </div> <b>(57) Abstract</b> Phosphorous derivatives having structure (i), processes for their preparation and their use as collagenase inhibitors.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

- 1 -

PHOSPHONOPEPTIDES WITH COLLAGENASE INHIBITING ACTIVITY

The present invention relates to novel phosphorus derivatives, processes for their preparation and their use  
5 in medicine. In particular, the present invention relates to their use as inhibitors of enzymes of the collagenase family of neutral metalloproteases, for treating arthritic and other diseases.

10 The mammalian collagenase family of enzymes comprises a number of proteases, exemplified by interstitial (type I) collagenase itself, the stromelysins (also known as proteoglycanases or transins), fibroblast and polymorphonuclear leucocyte gelatinases (also known as  
15 collagen-IV-ases), and 'pump-1' (putative metalloprotease 1, uterine metalloprotease). Membership of the mammalian collagenase family of proteases is evident by possession of a number of highly characteristic and experimentally verifiable properties. [Goldberg et al., J. Biol. Chem.  
20 2610, 6600, 1986; Whitham et al., Biochem. J. 240, 913, 1986; Breathnach et al., Nucleic Acids Res., 15, 1139, 1987; Muller et al., Biochem. J., 253, 187, 1988; Collier et al., J. Biol. Chem., 263, 6579, 1988; Murphy et al., Biochem. J., 258, 463, 1989; Quantin et al., Biochem.  
25 (N.Y.), 28, 5327, 1989; Birkedal-Hansen, J. Oral Pathol., 17, 445, 1988].

The range of therapeutic applications of the invention described hereinafter reflects the fundamental role of  
30 collagen and other proteinaceous substrates of the collagenase family of enzymes in the connective tissue matrix throughout the body. Applications extend to clinical interventions in many diseases and phenomena involving the destruction of collagen and other connective  
35 tissue components, and also normal or disordered tissue remodelling.

SUBSTITUTE SHEET

- 2 -

Inhibitors of the collagenase family of enzymes are considered to provide useful treatments for: arthritic diseases, such as rheumatoid and osteoarthritis, soft tissue rheumatism, polychondritis and tendonitis; bone resorption diseases, such as osteoporosis, Paget's disease, hyperparathyroidism and cholesteatoma; the enhanced collagen destruction that occurs in association with diabetes; the recessive classes of dystrophic epidermolysis bullosa; periodontal disease and related consequences of gingival production of collagenase, or of PMNL collagenase release following cellular infiltration to inflamed gingiva, including by combating the greater susceptibility of diabetes patients to periodontal disease; corneal ulceration, e.g. that induced by alkali or other burns, by radiation, by vitamin E or retinoid deficiency; ulceration of the skin and gastro-intestinal tract, and abnormal wound healing; post-operative conditions, including colonic anastomosis, in which collagenase levels are raised; cancer, where members of the collagenase family of enzymes have been implicated in the neovascularization required to support tumour growth and survival [P. Basset *et al.*, Nature, 348, 699, 1990] in the tissue remodelling required to accommodate the growing primary and secondary tumours, and in the penetration of tumour cells through the basement membrane of the vascular walls during metastasis; and demyelinating diseases of the central and peripheral nervous systems, including syndromes in which myelin loss is the primary pathological event and those in which demyelination follows axonal atrophy. The degradation of myelin in these diseases, exemplified by multiple sclerosis, is mediated by members of the collagenase family of enzymes.

SUBSTITUTE SHEET

- 3 -

As a particular example of the therapeutic value of inhibitors of the collagenase family of enzymes such as are disclosed in the present invention, chronic arthritic diseases leading to extensive loss of the collagen, proteoglycan and elastin components of the cartilage, bone and tendons within the joints, should be amenable to treatment with inhibitors of the collagenases, proteoglycanases (stromelysins) and gelatinases currently thought to be the major enzymes involved.

10

These enzymes have been detected in extracts of synovial and cartilage tissue, and have also been extensively studied in tissue cultures of a wide range of connective tissues. Apart from control of the biosynthesis, secretion and activation of the enzymes, the most important natural regulation of these enzymes in normal and diseased states, is considered to be the endogenous production of inhibitors such as the family of Tissue Inhibitor of Metalloproteases (TIMPS), and alpha-2 macroglobulin. An imbalance between the local levels of the proteolytic enzymes and natural inhibitors will allow destruction of connective tissue components to occur.

The compounds described in the present invention, being synthetic and low molecular weight inhibitors of this family of enzymes, offer a therapeutically useful way in which a more normal or non-pathological balance between inhibition and enzymic activity can be restored: they thus act to complement and supplement the endogenous enzyme inhibitors. Indeed, because these enzymes usually act only within restricted pericellular environments, before being inactivated by inhibitors circulating in the blood and present in most inflammatory exudates, the low molecular weight inhibitors disclosed here may be more

30

SUBSTITUTE SHEET

- 4 -

effective than endogenous proteinaceous inhibitors that are excluded by their size from the localized regions of connective tissue destruction.

- 5 European Patent Application 88310492.9 (Beecham Group) discloses a class of phosphorus derivatives having activity as inhibitors of collagenase and utility in the treatment of rheumatoid arthritis and related diseases in which collagenolytic activity is a contributing factor.

10


Novel structurally related compounds have now been discovered, which are collagenase inhibitors and thus of potential utility in the treatment of diseases in which collagenolytic activity and tissue remodelling is

15

implicated.

According to the present invention there is provided a compound of general formula (I), or a salt, solvate or hydrate thereof:

20



25

(I)

in which,

R is hydrogen, C<sub>1-6</sub> alkyl or optionally substituted

30 benzyl;

R<sub>1</sub> is hydrogen or C<sub>1-6</sub> alkyl;

R<sub>2</sub> is C<sub>3-6</sub> alkyl;


R<sub>3</sub> is -(CH<sub>2</sub>)<sub>n</sub>NR<sub>5</sub>R<sub>6</sub>, -(CH<sub>2</sub>)<sub>n</sub>NHCOR<sub>7</sub>, -(CH<sub>2</sub>)<sub>n</sub>CONH(CH<sub>2</sub>)<sub>q</sub>NR<sub>5</sub>R<sub>6</sub>,  
 -(CH<sub>2</sub>)<sub>n</sub>NR<sub>8</sub>C(=NR<sub>9</sub>)NR<sub>5</sub>R<sub>6</sub> or -(CH<sub>2</sub>)<sub>n</sub>-R<sub>10</sub> where n is an

35 integer from 1 to 6 and each of R<sub>5</sub> and R<sub>6</sub> is independently

**SUBSTITUTE SHEET**

- 5 -

- hydrogen or alkyl, or  $R_5$  and  $R_6$  together with the nitrogen atom to which they are bonded form a 5-, 6- or 7-membered ring with an optional oxygen or sulphur atom or an optionally substituted second nitrogen atom in the ring,
- 5  $R_7$  is alkyl or  $-(CH_2)_nNR_5R_6$ ,  $R_8$  is hydrogen or alkyl,  $R_9$  is hydrogen or alkyl or  $R_9$  and  $R_5$  together with the nitrogen atoms to which they are bonded form an optionally substituted 5-, 6- or 7-membered ring, and  $R_{10}$  is an optionally substituted piperidyl ring;
- 10  $m$  is 1 or 2, and  $q$  is 2 to 4; and  $R_4$  is hydrogen, alkyl, and  $-CH_2-(CH_2)_nOR_{11}$  or  $-CH_2-(CH_2)_nOCOR_{12}$  or



- where  $n$  is an integer from 1 to 6;  $R_{11}$ ,  $R_{12}$  and  $R_{13}$  are hydrogen or  $C_{1-6}$ alkyl; and  $R_{14}$  is hydroxy or  $-O-C_{1-6}$ alkyl or  $-NR_5R_6$  (where  $R_5$  and  $R_6$  may be linked to form a
- 20 heterocyclic ring).

- Unless otherwise specified, each alkyl group is preferably a  $C_{1-8}$  group, more preferably  $C_{1-6}$ , and may be a straight chain or branched.

25

$R$  is preferably hydrogen, methyl or ethyl, especially hydrogen.

- Values for  $R_1$  include hydrogen, methyl, ethyl, isopropyl
- 30 and n-butyl. As an alkyl group,  $R_1$  is preferably methyl or ethyl.

- $R_2$  is preferably a  $C_4$  alkyl group, such as n-butyl, iso-butyl or sec-butyl, especially iso-butyl.

35

**SUBSTITUTE SHEET**

- 6 -

Values for  $R_3$  include  $-(CH_2)_nNR_5R_6$  where  $R_5$  and  $R_6$  are hydrogen or methyl,  $-(CH_2)_nNHCOR_7$  where  $R_7$  is  $-(CH_2)_mNR_5R_6$  in which  $m$  is 1 and  $R_5$  and  $R_6$  are hydrogen,  $-(CH_2)_nCONH(CH_2)_qNR_5R_6$  where  $q$  is 2 and  $R_5$  and  $R_6$  together with the nitrogen atom to which they are bonded form a 5-, 6- or 7-membered ring,  $-(CH_2)_nNR_8C(=NR_9)NR_5R_6$  where  $R_5$ ,  $R_6$ ,  $R_8$  and  $R_9$  are all hydrogen,  $-(CH_2)_nNR_8C(=NR_9)NR_5R_6$  where  $R_5$  and  $R_9$  together with the nitrogen atoms to which they are bonded form an optionally substituted 2-imidazolinyll group,  $-(CH_2)_nR_{10}$  where  $R_{10}$  is optionally substituted piperidyl, and  $n$  is an integer from 1 to 4.

Most preferably  $R_3$  is  $-(CH_2)_nNR_5R_6$  where  $n$  is 3 or 4 and  $R_5$  and  $R_6$  are both hydrogen or methyl,  $-(CH_2)_4NHCOR_7$  where  $R_7$  is  $-CH_2NH_2$ ,  $-CH_2CONH(CH_2)_2NR_5R_6$  where  $R_5$  and  $R_6$  are joined together to form a pyrrolidine ring,  $-(CH_2)_nNR_8C(=NR_9)NR_5R_6$  where  $n$  is 3 or 4 and  $R_5$ ,  $R_6$ ,  $R_8$  and  $R_9$  are all hydrogen,  $-(CH_2)_4NR_8C(=NR_9)NR_5R_6$  where  $R_5$  and  $R_9$  together with the nitrogen atoms to which they are bonded form an optionally substituted 2-imidazolinyll group and  $R_6$  and  $R_8$  are both hydrogen,  $-(CH_2)_nNHC(=NH)NH_2$  where  $n$  is 3 or 4, and  $-CH_2R_{10}$  where  $R_{10}$  is 4-piperidyl.

Preferred values for  $R_4$  are methyl, ethyl,  $-(CH_2)_2OCH_3$ ,  $-CH(CH_3)CO_2CH_3$  and  $-(CH_2)_2OH$ , especially methyl and  $-(CH_2)_2OH$ .

The compounds of formula (I) may form salts with bases e.g. sodium hydroxide. The compounds of formula (I) have a basic nitrogen atom and may form acid addition salts e.g. with hydrochloric acid. Such compounds form part of the present invention.

SUBSTITUTE SHEET



- 7 -

Where compounds of formula (I), or salts thereof, form solvates or hydrates, these also form an aspect of the invention.

- 5 The compounds of formula (I) have at least two, and may have three or more asymmetric centres and therefore exist in more than one stereoisomeric form. The invention extends to all such forms and to mixtures thereof, including racemates, and diastereoisomeric mixtures.

10

Preferred isomers are those having the S-configuration at the chiral centre bearing  $R_2$  and the S-configuration at the chiral centre bearing  $R_3$ , marked with an asterisk in formula (I).

15

The compounds of formula (I) or their salts, solvates or hydrates are preferably in pharmaceutically acceptable form. By pharmaceutically acceptable form is meant, inter alia, of a pharmaceutically acceptable level of purity  
20 excluding normal pharmaceutical additives such as diluents and carriers, and including no material considered toxic at normal dosage levels.

- The compounds of formula (I) or their salts, solvates or  
25 hydrates are preferably in substantially pure form. A substantially pure form will generally contain at least 50% by weight, preferably 75%, more preferably 90% and still more preferably 95% or 99% or more of the compound of formula I or its salt or solvate.

30

Compounds of formula (I) or their salts, solvates or hydrates may be isolated as crystalline solids or in the form of foams or gums.

- 35 A preferred pharmaceutically acceptable form is the crystalline form.

**SUBSTITUTE SHEET**

- 8 -

The present invention provides the compounds of formula (I) or pharmaceutically acceptable salts, solvates or hydrates thereof for use as active therapeutic agents, particularly as agents for treatment of conditions in which degradation of connective tissue and other proteinaceous components of the body occurs, such as musculo-skeletal disorders resulting from collagenolytic activity, particularly rheumatism and/or arthritic conditions, and tissue remodelling.


10

Compounds of formula (I) also have potential utility in the treatment of cancer; for preventing myelin degradation in the central and peripheral nervous system; and in other conditions in which members of the collagenase family of neutral metalloproteases have pathological or other roles.

15

The present invention also provides a process for the preparation of a compound of formula (I) which comprises converting a group  $R_{20}$  to hydrogen by cleaving a group  $R_{20}$  from a compound of formula (II):

20



wherein  $R_{20}$  is alkyl, optionally substituted phenyl or optionally substituted benzyl and  $R_{21}$  is hydrogen, alkyl, optionally substituted phenyl or optionally substituted benzyl and  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  are as defined in formula (I), and where necessary, converting  $R_{21}$  to hydrogen, and optionally thereafter converting the compound of formula (I) to a further compound of formula (I).

35

SUBSTITUTE SHEET

- 9 -

Cleavage of  $R_{20}$ , and where necessary  $R_{21}$ , may be carried out in aqueous acid or alkali or using a trimethylsilyl halide, preferably bromotrimethylsilane, in an inert solvent, for example dichloromethane or acetonitrile.

5 Benzyl esters may alternatively be removed by hydrogenolysis or other standard debenzylation procedures. Phenyl residues may be removed by hydrogenation over platinum oxide.

10 When both  $R_{20}$  and  $R_{21}$  are alkyl, cleavage of  $R_{20}$  only, to give to a compound of formula (II) in which  $R_{20}$  is hydrogen and  $R_{21}$  alkyl, which is a compound of formula (I) in which R is alkyl, may be carried out by treatment with excess alkali under mild conditions, for example with  
15 aqueous sodium hydroxide in an alcoholic solvent at room temperature.

Similarly, where  $R_{20}$  is optionally substituted benzyl and  $R_{21}$  is alkyl, the benzyl group only may be cleaved by  
20 hydrogenation to give a compound of formula (II) in which  $R_{20}$  is hydrogen and  $R_{21}$  is alkyl.

Cleavage of an  $R_{21}$  alkyl group may thereafter be carried out as described above to give a compound of formula (I)  
25 in which R is hydrogen.

When R in a compound of formula (I) is hydrogen and  $R_{21}$  in a compound of formula (II) is not hydrogen, then cleavage of both  $R_{21}$  and  $R_{20}$  is conveniently effected in a single  
30 reaction. Preferably  $R_{20}$  and  $R_{21}$  are both alkyl, such as methyl or ethyl, or benzyl.


It will be appreciated that compounds of formula (II) in which  $R_{21}$  is hydrogen are themselves compounds of the  
35 invention of formula (I).

**SUBSTITUTE SHEET**

- 10 -

A compound of formula (I) in which  $R_3$  is  
 $-(CH_2)_nNR_8C(=NR_9)NR_5R_6$  in which  $R_5$ ,  $R_6$ ,  $R_8$  and  $R_9$  are as  
 defined in formula (I) may be prepared by reacting a  
 compound of formula (I) in which  $R_3$  is  $-(CH_2)_nNR_5R_6$  in  
 5 which  $R_5$  and  $R_6$  are either both hydrogen or one is  
 hydrogen and the other is alkyl with a compound of formula  
 (IIA)

10



(IIA)


15

or a salt thereof in which  $R_5$ ,  $R_6$  and  $R_9$  are as defined in  
 formula (I) and  $R_{15}$  is  $C_{1-6}$ alkyl. The reaction may be  
 carried out in the presence of a base such as sodium  
 bicarbonate in a suitable solvent such as water.

20

Compounds of formula (II) may be prepared by treating a  
 compound of formula (III):

25




(III)

SUBSTITUTE SHEET

- 11 -

in which  $R_1$ ,  $R_2$ ,  $R_{20}$  and  $R_{21}$  are as defined in formula (II) (except that  $R_{21}$  is not H), with a compound of formula (IV):

5



10

(IV)

in which  $R_3$  and  $R_4$  are as defined in formula (I), and any reactive amine group in  $R_3$  is in protected form.

15 The reaction is preferably carried out in the presence of a coupling agent, such as dicyclohexylcarbodiimide or 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride in the presence of 1-hydroxybenzotriazole, or using 1,1'-carbonyldiimidazole, in an inert solvent  
20 such as dichloromethane or acetonitrile.

Compounds of the formula (II) in which  $R_3$  is  $-(\text{CH}_2)_n-\text{R}_{10}$  where  $n$  and  $\text{R}_{10}$  are as defined in formula (I) can be prepared from the compound of formula (II) in which  $R_3$  is  
25  $-(\text{CH}_2)_n-\text{Z}$  where  $n$  is as defined in formula (I) and  $\text{Z}$  is an optionally substituted pyridyl ring, by hydrogenation in the presence of a noble metal catalyst.

It will be appreciated that when  $R_3$  is in protected form,  
30 the protecting group may be chosen to undergo concomitant cleavage with  $R_{20}$  and/or  $R_{21}$ .

SUBSTITUTE SHEET


- 12 -

Selective cleavage of the group  $R_{21}$  may then be carried out using the procedures described above for the preparation of compounds of formula (I) to give compounds of formula (II) in which  $R_{21}$  is hydrogen.

5

The intermediate compounds of formula (III) may be prepared by treating a compound of formula (V) or a salt thereof:

10




(V)


15

in which  $R_1$ ,  $R_{20}$  and  $R_{21}$  are as defined in formula (III), with a compound of formula (VIA) or (VIB) or a salt thereof:

20



(VIA)



(VIB)

25

in which  $R_2$  is as defined in formula (I),  $R_{16}$  is a leaving group such as halogen, methanesulphonyloxy or trifluoromethanesulphonyloxy and  $R_{17}$  is hydrogen or a carboxyl protecting group, and thereafter removing an  $R_{17}$  carboxyl protecting group. The preferred method is the reaction of (V) with (VIA).

30

SUBSTITUTE SHEET

- 13 -

When a compound of formula (VIB) is used, the reductive amination may be carried out by hydrogenation over a noble metal catalyst such as palladium on carbon or by reaction with sodium cyanoborohydride at pH 6 to 7. Lower alkyl  
5 alcohol solvents such as methanol and ethanol are suitable for both reactions. These reactions may be carried out in the presence of molecular sieves.

A hydrogenation reaction is preferred but this process  
10 precludes the use of compounds of formulae (V) and (VIB) in which any of  $R_{20}$ ,  $R_{21}$  or  $R_{17}$  is benzyl. Preferably a carboxyl protecting group is a methyl or ethyl ester. Ester protecting groups may be removed under standard basic hydrolysis conditions using dilute base such as 1  
15 Normal aqueous sodium hydroxide in methanol, or aqueous potassium hydroxide in 1,4-dioxane.

When the compound of formula (V) is in the form of the free base, the compound of formula (VIB) is suitably an  
20  $\alpha$ -keto ester ( $R_{17}$  = alkyl).

When the compound of formula (V) is a salt, such as the hydrochloride salt, the compound of formula (VIB) is suitably a salt of an  $\alpha$ -keto acid ( $R_{17}$  = H), for example  
25 the sodium salt.


The preparation of compounds of formula (III) using a compound of formula (VIA) may be carried out under standard alkylation conditions. A halogen leaving group  
30 is preferably bromine and an oxygen-based leaving group is preferably trifluoromethanesulphonyloxy.

SUBSTITUTE SHEET

- 14 -


Compounds of formula (III) may alternatively be prepared by condensing a compound of formula (VII) or a salt thereof:

5



- 10 in which  $\text{R}_2$  is as defined in formula (I) and  $\text{R}_{17}$  is a carboxyl protecting group with an aldehyde,  $\text{R}_1\text{-CHO}$  in which  $\text{R}_1$  is as defined in formula (I) and treating the condensation product with an appropriate dialkyl or trialkyl phosphite, for example dimethyl phosphite, and
- 15 thereafter removing the carboxyl protecting group. The carboxyl group is conveniently protected as an alkyl or benzyl ester which may be removed using standard hydrolysis or hydrogenation conditions.
- 20 As described above in connection with reductive amination of compounds of formula (VIB), where a benzyl protecting group  $\text{R}_{17}$  is removed by hydrogenation then  $\text{R}_{20}$  and  $\text{R}_{21}$  are restricted to alkyl.
- 25 Alternatively, compounds of formula (II) in which  $\text{R}_{20}$  and  $\text{R}_{21}$  are alkyl or optionally substituted benzyl may be prepared by the reaction of a compound of formula (VIII):

30




35

SUBSTITUTE SHEET



- 15 -

in which  $R_2$ ,  $R_3$  and  $R_4$  are as defined in formula (I), with a compound of formula (IX):



(IX)

10

in which  $R_1$  is as defined in formula (I),  $R_{20}$  and  $R_{21}$  are alkyl, optionally substituted phenyl, or optionally substituted benzyl and  $R_{16}$  is a leaving group as defined for formula (VIA), in the presence of a base such as triethylamine or Proton Sponge (1,8-bis(dimethylamino)-naphthalene), or using anhydrous potassium carbonate in an alcoholic solvent.

Where  $R_{16}$  is an oxygen-based leaving group, for example trifluoromethanesulphonyloxy, which is preferred, displacement of the leaving group is conveniently carried out in the presence of Proton Sponge in an inert solvent such as acetonitrile or dichloromethane, over a period of several days in the absence of light.

25

A further alternative preparation of compounds of formula (III) may be carried out by reacting a compound of formula (IX) as hereinbefore defined with a compound of formula (VII) in which  $R_{17}$  is a carboxyl protecting group, using conditions as described for the reaction of compounds of formula (VIII) with compounds of formula (IX), and thereafter removing the protecting group  $R_{17}$ .

SUBSTITUTE SHEET

- 16 -


Suitable carboxyl protecting groups include alkyl, benzyl, trialkylsilyl, and trialkylsilylethyl groups. A trialkylsilyl protecting group, for example trimethylsilyl, is especially useful in that it may be readily incorporated, in situ, for example by addition of hexamethyldisilazane to the reactants in acetonitrile in the presence of triethylamine, and selectively removed in aqueous methanol, without imposing any limitations on the value of  $R_{20}$  and  $R_{21}$ . Other silylating agents include trimethylsilyl chloride and N,N-diethyltrimethylsilylamine.

An  $R_{17}$  alkyl carboxyl protecting group may be removed by base hydrolysis, for example using sodium hydroxide in aqueous methanol or potassium hydroxide in aqueous 1,4-dioxane.

It will be appreciated that where the carboxyl protecting group  $R_{17}$  is alkyl,  $R_{20}$  and  $R_{21}$  may be alkyl, phenyl or benzyl derivatives, but where  $R_{17}$  is a benzyl group,  $R_{20}$  and  $R_{21}$  are limited to alkyl and phenyl.

When compounds of formula (III) are prepared by this route, it is preferred that  $R_{20}$  and  $R_{21}$  are benzyl and  $R_{16}$  is trifluoromethanesulphonyloxy in the compound of formula (IX) and  $R_{17}$  is trimethylsilyl or methyl in the compound of formula (VII).

Compounds of formula (VIII) may be prepared by treating a compound of formula (VII):



SUBSTITUTE SHEET

- 17 -

in which  $R_2$  is as defined in formula (I),  $R_{17}$  is hydrogen and wherein the amino group is optionally protected, with a compound of formula (IV) as hereinbefore defined, in the presence of a coupling agent as hereinbefore described for the preparation of compounds of formula (II) from compounds of formulae (III) and (IV).

Compounds of formula (IX) may be prepared from hydroxyalkylphosphonate derivatives by conversion of the hydroxyl group to the leaving group  $R_{16}$  by conventional methods. For example, where  $R_{16}$  is trifluoromethanesulphonyloxy, trifluoromethanesulphonic anhydride may be added to a solution of the hydroxyalkylphosphonate in an inert solvent such as dichloromethane, the reaction being carried out at reduced temperature under an inert atmosphere, according to the general method of E. Vedejs *et al.*, Journal of Organic Chemistry 50, 2165, (1985).

Hydroxyalkylphosphonate compounds may in turn be prepared by reaction of the corresponding phosphite, for example dibenzylphosphite, with an aldehyde  $R_1$ -CHO in which  $R_1$  is as defined in formula (I) according to the general method of F. Texier-Boullet and A. Foucaud, Synthesis, 916 (1982). Benzyl and alkyl phosphites are either commercially available compounds or can be prepared from commercially available starting materials by standard methods.

Intermediate compounds of formula (V) are either known compounds or may be prepared from known aminoalkyl phosphonic acid derivatives using standard procedures to introduce  $R_{20}$  and  $R_{21}$  as required.

Protection of the amine function during these reactions may be necessary.

SUBSTITUTE SHEET


- 18 -

Introduction of an R<sub>20</sub> or R<sub>21</sub> methyl group may be effected by reaction with diazomethane in a suitable inert solvent.

Compounds of formula (V) of fixed configuration may be prepared by the general method of R. Jacquier *et al.*, Phosphorus and Sulfur 36, 73, (1988).

Compounds of formula (IV) may be prepared from amino acid derivatives, many of which are commercially available, by conventional alkylation or coupling reactions.

Thus a compound of formula (IV) may be prepared from a compound of formula (X):



20

in which Q is  $-(\text{CH}_2)_n\text{-Z}$ ,  $-(\text{CH}_2)_n\text{NH}_2$ ,  $-(\text{CH}_2)_n\text{NR}_8\text{C}(=\text{NH})\text{NH}_2$ ,  $-(\text{CH}_2)_n\text{NR}_8\text{C}(=\text{NH})\text{NO}_2$  or  $-(\text{CH}_2)_n\text{CO}_2\text{H}$ , n, R<sub>4</sub> and R<sub>8</sub> are as defined in formula (I), Z is optionally substituted pyridyl and Y is a nitrogen protection group, by conversion of Q to R<sub>3</sub> and removal of the nitrogen protection group, Y. It will be appreciated that the conversion of Q to R<sub>3</sub> may be most readily effected at a later stage, for example conversion of  $(\text{CH}_2)_n\text{NHC}(=\text{NH})\text{NHNO}_2$  to  $(\text{CH}_2)_n\text{NHC}(=\text{NH})\text{NH}_2$  by hydrogenation can be concomitant with hydrogenolysis of R<sub>20</sub> and R<sub>21</sub> benzyl groups.

SUBSTITUTE SHEET

- 19 -

A compound of formula (IV) in which  $R_3$  is  $-(CH_2)_nNR_5R_6$  may be prepared by alkylation of a compound of formula (X) in which  $Q$  is  $-(CH_2)_nNH_2$  using standard alkylation procedures.

5

A compound of formula (IV) in which  $R_3$  is  $-(CH_2)_nNHCOR_7$  may be prepared by reaction of a compound of formula (X) in which  $Q$  is  $-(CH_2)_nNH_2$  with a carboxylic acid  $R_7CO_2H$ , in the presence of a coupling agent.

10

A compound of formula (IV) in which  $R_3$  is  $-(CH_2)_nCONH(CH_2)_qNR_5R_6$  may be prepared by reaction of a compound of formula (X) in which  $Q$  is  $-(CH_2)_nCO_2H$  with an amine derivative,  $NH_2(CH_2)_qNR_5R_6$  in the presence of a coupling agent, and thereafter if  $R_5$  or  $R_6$  is hydrogen optionally protecting the basic nitrogen atom.

15

A compound of formula (IV) in which  $R_3$  is  $-(CH_2)_nNR_8C(=NR_9)NR_5R_6$  may be prepared from a compound of formula (X) in which  $Q$  is  $-(CH_2)_nNR_8C(=NH)NH_2$  or  $-(CH_2)_nNH_2$  by N-alkylation and optionally thereafter protecting the basic nitrogen atoms.

20

A compound of the formula (IV) in which  $R_3$  is  $-(CH_2)_n-R_{10}$  where  $R_{10}$  is a piperidyl group may be prepared by hydrogenation of a compound of formula (X) in which  $R_3$  is  $-(CH_2)_n-Z$  and optionally thereafter protecting the piperidyl nitrogen atom.

25

Suitable nitrogen protection groups for  $Y$  and for any primary amino function in  $R_3$  include  $t$ -butoxycarbonyl (BOC) and benzyloxycarbonyl groups. When  $R_3$  is  $-(CH_2)_n-R_{10}$  where  $R_{10}$  is 4-piperidyl, a suitable nitrogen protecting group includes the benzyloxycarbonyl group.

30

35


SUBSTITUTE SHEET

- 20 -

Nitrogen protection groups may be removed by standard methods. A t-butoxycarbonyl group may be removed by treatment with trifluoroacetic acid at reduced temperature. Benzyloxycarbonyl groups may be removed by  
5 catalytic hydrogenation.

A compound of formula (X) may be prepared from a compound of formula (XI):

10



(XI)

15 wherein Q' is Q in protected form or Q' is a precursor to Q and Y and Q are as defined for formula (X).

The reaction may be carried out by reaction with an amine,  $\text{NH}_2\text{R}_4$ , using standard procedures for forming an amide from  
20 a carboxylic acid and an amine, for example using a coupling agent such as 1,1'-carbonyldiimidazole, 1,3-dicyclohexylcarbodiimide or 1-ethyl-3-[3-(dimethyl-amino)propyl]carbodiimide, or in the presence of ethyl chloroformate.

25

Compounds of formula (XI) are known compounds or may be prepared from known starting materials by standard methods.

30 For example the compound of formula (XI) in which Q' is  $(\text{CH}_2)_4\text{NHC(O)OCH}_2\text{Ph}$  and Y is t-butoxycarbonyl is derived from lysine and is commercially available.

- 21 -

The compound of formula (XI) in which Q' is  $\text{CH}_2\text{CO}_2\text{CH}_2\text{Ph}$  and Y is t-butoxycarbonyl is derived from aspartic acid and is commercially available.

- 5 Compounds of formula (IIA) and (IIB) are commercially available or may be prepared from known starting materials using standard procedures.

- The compound of formula (XI) in which Q' is a group  
10  $-(\text{CH}_2)_n-\text{Z}$  where Z is 4-pyridyl and Y is t-butoxycarbonyl is prepared according to the method of R.L. Bixler and C. Niemann, J. Org. Chem., 23, 575 (1958).

- The compounds of formula (VII) are either known amino acid  
15 derivatives or can be made from these derivatives by known methods. Compounds of formula (VIA) and (VIB) are either known compounds or may be prepared from known compounds by known methods.

- 20 The intermediates of formula (II) disclosed herein are novel compounds and form an aspect of the present invention as do the described processes for their preparation.

- 25 Where obtainable, pharmaceutically acceptable salts of the compounds of formula (I) may be formed conventionally by reaction with the appropriate acid or base. Solvates may be formed by crystallization from the appropriate solvent.

- 30 As mentioned previously, the compounds of formula (I) exist in more than one diastereoisomeric form. Where the processes of the invention produce mixtures thereof, the individual isomers may be separated one from another by chromatography e.g. HPLC.

35

**SUBSTITUTE SHEET**

- 22 -

Alternatively, separate diastereoisomeric compounds of formula (I) can be obtained by using stereoisomerically pure starting materials or by separating desired isomers of intermediates at any stage in the overall synthetic process, and converting these intermediates to compounds of formula (I).

It will be appreciated that where a single diastereoisomer of a compound of formula (I) is prepared by more than one process variant as hereinbefore described, each of which allows a different chiral centre to be defined, it may be possible to deduce the configuration at a chiral centre which is not pre-determined using a particular process variant.

Furthermore, it will be appreciated that although the absolute configuration at a particular chiral centre may not be known, it is possible to characterise a given diastereoisomer relative to its epimer by reference to the direction in which the plane of polarised light is rotated.

The present invention further provides a pharmaceutical composition, which comprises a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.

A composition of this invention is useful in the treatment of musculo-skeletal disorders, particularly arthritic diseases and for modulation of tissue remodelling.

A composition of the invention also has potential utility in the treatment of cancer; for preventing myelin degradation in the central and peripheral nervous system;

**SUBSTITUTE SHEET**



- 23 -

and in other conditions in which members of the collagenase family of neutral metalloproteases have pathological or other roles.

- 5 A composition of the invention, which may be prepared by admixture, may contain a diluent, binder, filler, disintegrant, flavouring agent, colouring agent, lubricant or preservative in conventional manner. These conventional excipients may be employed in conventional  
10 manner, for example as in the preparation of compositions of related peptide enzyme inhibitors, such as the ACE inhibitor enalapril.

A composition of the invention may be adapted for oral,  
15 topical, rectal or parenteral administration but oral administration is preferred. Parenteral compositions may be administered intravenously, intramuscularly, intra-articularly, intradermally, subcutaneously or into the cerebro-spinal fluid.

20 Preferably, a pharmaceutical composition of the invention is in unit dosage form and in a form adapted for use in the medical or veterinarial fields. For example, such preparations may be in a pack form accompanied by written  
25 or printed instructions for use as an agent in the treatment or prophylaxis of any of the disorders mentioned above.

The suitable dosage range for the compounds of the  
30 invention may vary from compound to compound and may depend on the condition to be treated. It will also depend, inter alia, upon the relation of potency to absorbability and the mode of administration chosen.

- 24 -

The compound or composition of the invention may be formulated for administration by any route, the preferred route depending upon the disorder for which treatment is required, and is preferably in unit dosage form or in a form that a human patient may administer to himself in a single dosage.

Compositions may, for example, be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, reconstitutable powders, or liquid preparations, for example solutions or suspensions, or suppositories.

The compositions, for example those suitable for oral administration, may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tableting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable wetting agents such as sodium lauryl sulphate.

Solid compositions may be obtained by conventional methods of blending, filling, tableting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. When the composition is in the form of a tablet, powder, or lozenge, any carrier suitable for formulating solid pharmaceutical compositions may be used, examples being magnesium stearate, starch, glucose, lactose, sucrose, rice flour and chalk. Tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric

**SUBSTITUTE SHEET**

- 25 -

coating. The composition may also be in the form of an ingestible capsule, for example of gelatin containing the compound, if desired with a carrier or other excipients.

For example, in a hard gelatin capsule containing the  
5 required amount of a compound of the invention in the form of a powder or granulate in intimate mixture with a lubricant, such as magnesium stearate, a filler, such as microcrystalline cellulose, and a disintegrant, such as sodium starch glycollate.

10

Compositions for oral administration as liquids may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such  
15 liquid compositions may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example  
20 lecithin, sorbitan monooleate, or acacia; aqueous or non-aqueous vehicles, which include edible oils, for example almond oil, fractionated coconut oil, oily esters, for example esters of glycerine, or propylene glycol, or ethyl alcohol, glycerine, water or normal saline;  
25 preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.

The compounds of this invention may also be administered  
30 by a non-oral route. In accordance with routine pharmaceutical procedure, the compositions may be formulated, for example for rectal administration as a suppository or for parenteral administration in an injectable form. For injection, for example by  
35 intra-articular injection or by injection into the cerebro-spinal fluid or via other routes which will gain

**SUBSTITUTE SHEET**

- 26 -

access to sites of demyelination, such as by intramuscular, intradermal or subcutaneous injection, as freely soluble solutions or as poorly dispersed depot stores, the compounds of the invention may be presented in  
5 an aqueous or non-aqueous solution, suspension or emulsion in a pharmaceutically acceptable liquid, e.g. sterile pyrogen-free water or a parenterally acceptable oil or a mixture of liquids, which may contain bacteriostatic agents, anti-oxidants or other preservatives, buffers or  
10 solutes to render the solution isotonic with the blood, thickening agents, suspending agents or other pharmaceutically acceptable additives. Such forms will be presented in sterile unit dose form such as ampoules or disposable injection devices or in multi-dose forms such  
15 as a bottle from which the appropriate dose may be withdrawn or a solid form or concentrate which can be used to prepare an injectable formulation.

For topical and percutaneous administration, the  
20 preparations may also be presented as an ointment, cream, lotion, gel, spray, aerosol, wash, skin paint or patch.

A unit dose for treating diseases in which enzymes of the collagenase family are involved will generally contain  
25 from 10 to 1000 mg and preferably will contain from 10 to 500 mg, in particular 10, 50, 100, 150, 200, 250, 300, 350, 400, 450 or 500 mg. The composition may be administered one or more times a day, for example 2, 3 or 4 times daily, so that the total daily dose for a 70 kg  
30 adult will normally be in the range 10 to 3000 mg. Such a dosage corresponds to approximately 0.15 to 50 mg/kg per day. Alternatively, in particular for injection, the unit dose will contain from 2 to 200 mg of a compound of the invention and be administered in multiples, if desired, to  
35 give the desired daily dose.

**SUBSTITUTE SHEET**

- 27 -

The present invention additionally provides a method of treating conditions in which degradation of connective tissue and other proteinaceous components of the body occurs, such as rheumatism and/or arthritic conditions in mammals, such as humans, which comprises administering to  
5 the mammal in need of such treatment an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.


10 The present invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in the treatment of conditions in which degradation of connective tissue and other proteinaceous components of  
15 the body occurs such as rheumatism and/or arthritic conditions.

The following Descriptions and Examples illustrate the preparation of compounds of the invention. All  
20 temperatures are expressed in °C.

- 28 -

Description 1Dibenzyl (1-hydroxypropyl)phosphonate (D1)

5



10

The general method of F. Texier-Boullet and A. Foucaud [Synthesis, 1982, 916] was employed. A mixture of dibenzyl phosphite (31.13 ml, 0.14 mole) and  
15 propionaldehyde (10.21 ml, 1 equiv.) was stirred at room temperature and basic alumina (70g) added in one portion. After standing overnight at room temperature chloroform was added and the alumina collected and washed with chloroform. The filtrate was evaporated to dryness and  
20 the resulting clear oil chromatographed on silica gel (600g) with gradient elution (ether - 5% methanol/ether). The title compound was obtained as a clear oil which solidified on standing (27.82g, 64%). A sample was recrystallized from ether/pentane to give a white  
25 crystalline solid, m.p. 81-82°C.

Found: C, 64.09; H, 6.71.  $\text{C}_{17}\text{H}_{21}\text{O}_4\text{P}_1$  requires C, 63.74; H, 6.61%.


30  $\delta$  ( $\text{CDCl}_3$ ): 1.04 (3H, t,  $J=7\text{Hz}$ ), 1.6-1.95 (2H, m), 2.27 (1H, br s), 3.8 (1H, 2 overlapping triplets,  $J=5$  and  $10\text{Hz}$ ), 4.97-5.18 (4H, m), 7.34 (10H, s).

SUBSTITUTE SHEET

- 29 -

Description 2Dibenzyl ((1-trifluoromethanesulphonyloxy)propyl)phosphonate (D2)

5



10

The title compound was prepared by the general method of E. Vedejs et al. [J. Org. Chem. 1985, 50(12), 2165]. A solution of dibenzyl (1-hydroxypropyl)phosphonate (D1) (24.97g, 0.078 mole) in methylene chloride (180 ml) was cooled to -50°C under N<sub>2</sub>. 2,6-Lutidine (11.12 ml, 0.095 mole) was added followed by trifluoromethanesulphonic anhydride (15.1 ml, 0.0898 mole) keeping the temperature at -50°C. The mixture was allowed to warm slowly to 0°C and then taken into cold ether. The solution was subjected to a rapid aqueous work-up by washing the organic layer with ice-cold water, dilute hydrochloric acid (x2) and finally brine. The organic layer was dried (anhydrous MgSO<sub>4</sub>) and evaporated to dryness to give the title compound as a pinkish orange oil (33.77g, 96%) which was used without further purification.


$\delta$  (CDCl<sub>3</sub>): 1.08 (3H, t, J=7Hz), 1.88 (2H, m), 4.94 (1H, 2 overlapping triplets, J=5.5 and 7Hz), 4.88-5.22 (4H, m) and 7.35 (10H, m).

SUBSTITUTE SHEET

- 30 -

Description 3

N-(1-(R)-Dibenzyloxyphosphinylpropyl)-(S)-leucine (D3A)  
and N-(1-(S)-Dibenzyloxyphosphinylpropyl)-(S)-leucine  
 5 (D3B)

Method A

Following the general method of US 4808741 for the  
 preparation of leucine trimethylsilyl ester a mixture of  
 15 (S)-leucine (1.15g, 0.0088 mole), hexamethyldisilazane  
 (1.75 ml), and triethylamine (1.38 ml) in acetonitrile  
 (13.5 ml) was heated at reflux for a total of 4h.

Dibenzyl ((1-trifluoromethanesulphonyloxy)propyl)-  
 20 phosphonate (D2) (4.5g, 0.01 mole) was then added and the  
 mixture maintained at 40-42°C for 48h. The reaction can  
 also be carried out at ambient temperature. After cooling  
 the mixture was filtered, washed with methanol and the  
 filtrate evaporated to dryness. The residue was taken up  
 25 in chloroform and washed with dilute HCl (x2) and finally  
 water. The chloroform layer was dried (anhydrous Na<sub>2</sub>SO<sub>4</sub>),  
 filtered and evaporated to dryness to give an orange gummy  
 solid (3.67g). The crude product was triturated with the  
 minimum volume of ether/pentane to give a white  
 30 crystalline solid which after collection, washing with a  
 little cold ether/pentane and drying gave the title  
 compound, R,S isomer (D3A) (0.47g, 11%), m.p. 112-115°C.

SUBSTITUTE SHEET



- 31 -

Observed Desorption CI ( $\text{NH}_3$ ) ( $\text{M}+\text{H}$ )<sup>+</sup> 434.  $\text{C}_{23}\text{H}_{32}\text{NO}_5\text{P}$  requires M 433.

$[\alpha]_{\text{D}}^{20} = -23.09^\circ$  ( $c=0.97$  MeOH).

Found: C, 63.73; H, 7.42; N, 3.23.  $\text{C}_{23}\text{H}_{32}\text{NO}_5\text{P}$  requires  
5 C, 63.73; H, 7.44; N, 3.23%.

$\delta$  ( $\text{CDCl}_3$ ): 0.89 (6H, t), 1.03 (3H, t), 1.25-2.0 (5H, m), 2.74 (1H, m), 3.28 (2H, br s), 3.73 (1H, br t), 4.9-5.15 (4H, m), 7.35 (10H, s).

10

The other isomer, N-(1-(S)-dibenzoyloxyphosphinylpropyl)-(S)-leucine (D3B), can be obtained by preparative HPLC using a Hamilton PRP-1 column, 300 x 7.0mm, 264R with a  
40:60 acetonitrile:water eluent mixture and a flow rate of  
15 4.0 ml/min. Under these conditions the R,S isomer (D3A) elutes first with a retention time of 34.6 min and the S,S isomer (D3B) is well separated at 42.7 min.

For the isomer (D3B):

20 Observed FAB ( $\text{M}+\text{H}$ )<sup>+</sup> 434.  $\text{C}_{23}\text{H}_{32}\text{NO}_5\text{P}$  requires M 433.

$\delta$  ( $\text{CDCl}_3$ ): 0.88 (6H, dd), 0.98 (3H, t), 1.4 (1H, m), 1.52-1.9 (4H, m), 2.72 (1H, m), 3.38 (1H, m), 4.9-5.15 (4H, m), 7.32 (10H, s).

25

The S,S isomer (D3B) on coupling with (S)-amino acid derivatives leads to the S,S,S, series.

#### Method B

30

A mixture of (S)-leucine methyl ester hydrochloride (0.543g; 0.003 mole), dibenzyl (1-trifluoromethanesulphonyloxy)propyl-phosphonate (D2) (1.35g; 0.003 mole) and anhydrous potassium carbonate (1.0g) in methanol  
35 (2 ml) was heated at 50°C, with stirring, for 4 hours and then left at room temperature overnight.

**SUBSTITUTE SHEET**

- 32 -

The reaction mixture was evaporated to dryness in vacuo, and dissolved in chloroform (5 ml) and filtered. The filtrate, and washings, were combined and chromatographed on silica gel 60 (50g) using ethyl acetate-pentane (1:1) as the eluent, to afford a mixture of N-(1-(R)-dibenzyl-oxyphosphinylpropyl)-(S)-leucine methyl ester and N-(1-(S)-dibenzyl-oxyphosphinylpropyl)-(S)-leucine methyl ester as an oil (0.55g). The esters can be separated into the individual diastereoisomers by column chromatography on silica gel with initially 50% diethyl ether/pentane as eluent, rising to 100% diethyl ether.

The above mixture of esters (1.1g, 0.0025 mole) in methanol (4.0 ml) was treated with a solution of sodium hydroxide (0.11g; 0.00275 mole) in water (1.5 ml), and the solution was stirred at room temperature overnight. It was evaporated to one third volume, in vacuo, taken in water and extracted with ether. The aqueous fraction was acidified with citric acid to pH 3-4 and then extracted (5x) with chloroform. The chloroform fraction was dried ( $\text{Na}_2\text{SO}_4$ ) and evaporated to dryness in vacuo to give a mixture of the title compounds (D3A) and (D3B) as an oil that slowly solidified.

Trituration of the product with ether gave N-(1-(R)-dibenzyl-oxyphosphinylpropyl)-(S)-leucine (D3A) (0.34g) as a white crystalline solid, identical to the product obtained by Method A.

Alternatively, the single isomer esters can be hydrolysed separately. For example N-(1-(S)-dibenzyl-oxyphosphinylpropyl)-(S)-leucine methyl ester on hydrolysis by the above method gave N-(1-(S)-dibenzyl-oxyphosphinylpropyl)-(S)-leucine (D3B), m.p. 71-73°C.


35

SUBSTITUTE SHEET

- 33 -

Description 4N<sup>α</sup>-tert-Butoxycarbonyl-N<sup>ε</sup>-benzyloxycarbonyl-(S)-lysine  
methanamide (D4)

5



10

A stirred solution of N<sup>α</sup>-tert-butoxycarbonyl-N<sup>ε</sup>-benzyloxycarbonyl-(S)-lysine (1.5g, 3.95 mmol) in anhydrous dichloromethane (30 ml) maintained at 0°C was sequentially treated with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.91g, 4.7 mmol) and 1-hydroxybenzotriazole (0.64g, 4.7 mmol). After 0.5 h, the mixture was warmed up to room temperature, methanamine bubbled through, and the resulting solution left stirring for 18 h. The solution was then filtered, washed with sat. aq. NaHCO<sub>3</sub>, dried over anhydrous magnesium sulphate and concentrated under reduced pressure to afford a solid. Purification by flash chromatography (5% methanol in chloroform) gave the title compound as a white solid (1.18g).

25

δ (CDCl<sub>3</sub>): 1.3-1.85 (6H,m), 1.42 (9H,s), 2.28 (3H,d), 3.19 (2H,q), 4.05 (1H,m), 4.88 (1H,m), 5.08 (2H,s), 5.15 (1H,m), 6.2 (1H,m), 7.35 (5H,m).

30


SUBSTITUTE SHEET

- 34 -

Description 5

N<sup>ε</sup>-Benzyloxycarbonyl-(S)-lysine methylamide,  
trifluoroacetate salt (D5)

5




10

A cooled (0°C) solution of the amide (D4) (0.3g, 0.76 mmol) in dichloromethane (5 ml) was treated with trifluoroacetic acid (2 ml). After 0.5 h the solvent was  
 15 evaporated under reduced pressure, the residue diluted with dichloromethane (15 ml) and washed with sat. aq. NaCl (10 ml). The organic fraction was dried over anhydrous magnesium sulphate and evaporated in vacuo to give crude  
 20 title compound (D5) (0.29g). This was used as such without further purification.

Description 6

N<sup>α</sup>-[N-((R)-1-Dibenzoyloxyphosphinylpropyl)-(S)-leucyl]-N<sup>ε</sup>-  
 25 benzyloxycarbonyl-(S)-lysine methylamide (D6)

30



35

SUBSTITUTE SHEET

- 35 -

A solution of N-(1-(R)-dibenzoyloxyphosphinylpropyl)-(S)-leucine (D3A) (0.33g, 0.76 mmol) in anhydrous dichloromethane (10 ml) was cooled to 0°C, and treated sequentially with

5 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.176g, 0.92 mmol) and 1-hydroxybenzotriazole (0.124g, 0.92 mmol). After stirring for 0.5 h the reaction mixture was treated with the salt (D5) (0.29g) followed by N,N-diisopropylethylamine (0.216g,


10 1.42 mmol). The mixture was stirred for 18 h at room temperature, then washed with sat. aq. NaHCO<sub>3</sub> (2x20 ml), and sat. aq. NaCl (2x20 ml). The aqueous washes were back-extracted with dichloromethane and the combined organic fractions dried over anhydrous magnesium sulphate,

15 and evaporated in vacuo to yield an oil. On purification by flash chromatography [(MeOH:CH<sub>2</sub>Cl<sub>2</sub>) (1:20) v/v then (1:9) v/v], the title compound was isolated as a white solid (0.20g).

20 Observed FAB (M+H)<sup>+</sup> 678. C<sub>38</sub>H<sub>53</sub>O<sub>7</sub>N<sub>4</sub> requires M 677.

#### Description 7

25 N<sup>α</sup>-tert-Butoxycarbonyl-N<sup>ε</sup>-(N-benzyloxycarbonyl-glycyl)-(S)-lysine methylamide (D7)



35

**SUBSTITUTE SHEET**

- 36 -

A stirred solution of N-benzyloxycarbonyl-glycine (1.8g, 5.82 mmol) in anhydrous dichloromethane (60 ml) was treated with 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (1.23g, 6.4 mmol) followed by 1-hydroxybenzotriazole (0.98g, 7.2 mmol). Stirring was continued for 0.5 h then treated with N<sup>α</sup>-tert-butoxycarbonyl-(S)-lysine methylamide (1.51g, 5.82 mmol) diluted in dichloromethane (5 ml), and left stirring. After 18 h the mixture was washed with sat. aq. NaHCO<sub>3</sub> (2x30 ml), dried over anhydrous magnesium sulphate and evaporated in vacuo to yield a pale yellow oil. Purification by flash chromatography afforded the title compound as a clear viscous oil which solidified on standing.


15

δ (CDCl<sub>3</sub>): 1.26-1.82 (6H,m), 1.42 (9H,s), 2.79 (3H,d), 3.26 (2H,m), 3.87 (2H,d), 4.05 (1H,m), 5.12 (2H,s), 5.28 (1H,m), 5.72 (1H,brs), 6.46 (1H,brs), 7.32-7.4 (5H,m).

20 Description 8

N<sup>ε</sup>-(N-Benzyloxycarbonyl)glycyl)-(S)-lysine methylamide, trifluoroacetate salt (D8)

25



30


SUBSTITUTE SHEET

- 37 -

A cool (0°C) solution of the amide (D7) (0.1g, 0.22 mmol) in dichloromethane (5 ml) was treated with trifluoroacetic acid (2 ml). After stirring at 0°C for 1 h, the solution was allowed to warm up to room temperature. The solvent was evaporated under reduced pressure, to yield the crude product (D8) which was used without further purification.

Description 9

10 N<sup>α</sup>-[N-((R)-1-Phosphonopropyl)-(S)-leucyl]-N<sup>ε</sup>-(N-benzyl-oxycarbonylglycyl)-(S)-lysine methylamide, dibenzyl ester (D9)



A solution of N-(1-(R)-dibenzylphosphinylpropyl)-(S)-leucine (D3A) (0.43g, 1 mmol) in anhydrous dichloromethane (20 ml) was treated with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.21g, 1.1 mmol) and 1-hydroxybenzotriazole (0.162g, 1.2 mmol). After stirring for 1 h, the salt (D8) (0.25g), diluted in dichloromethane (10 ml), was added followed by diisopropylethylamine (1 equiv.) stirring continued for a further 18 h. The mixture was then washed with sat. aq. NaHCO<sub>3</sub> (2x20 ml), dried over anhydrous magnesium sulphate and evaporated in vacuo to afford a yellow oil. Purification by flash

SUBSTITUTE SHEET

- 38 -

chromatography [(MeOH:CHCl<sub>3</sub>) (1:15) v/v] afforded the title compound as a white solid (0.4g).


5  $\delta$  (CDCl<sub>3</sub>): 0.96 (6H,t), 1.05 (3H,t), 1.2-2.4 (13H,m), 2.73 (3H,d), 3.18 (2H,m), 3.69 (1H,m), 3.82 (2H,d), 4.38 (1H,q), 4.88-5.03 (4H,m), 5.08 (2H,s), 6.35 (1H,t), 6.95 (1H,t), 7.08 (1H,q), 7.22-7.4 (15H,m), 7.51 (1H,d).

Description 10

10

N-tert-Butoxycarbonyl-(S)-aspartic acid methylamide (D10)

15



To a solution of N-tert-butoxycarbonyl-(S)-aspartic acid  
20  $\beta$ -benzyl ester (66g) in dry tetrahydrofuran (100 ml) at  
-10°C was added diisopropylethylamine (38 ml) followed by  
ethyl chloroformate (23 ml) and a solution of methylamine  
(10g) in dry tetrahydrofuran (30 ml) was added. After  
0.5h the reaction mixture was evaporated to dryness in  
25 vacuo and the residue, in ethyl acetate, was washed with  
10% sodium carbonate, citric acid and water, and dried  
(Na<sub>2</sub>SO<sub>4</sub>). Evaporation to dryness in vacuo, followed by  
trituration with ethyl acetate-ether (1:1) afforded a  
solid (45g) that was hydrogenated in ethanol (600 ml) over  
30 10% palladium on carbon (8g) until uptake of hydrogen  
ceased. The reaction mixture was filtered, and the

SUBSTITUTE SHEET



- 39 -


filtrate was evaporated to dryness to afford the title compound (D10) as a white solid (33.5g), m.p. 160-162°C (dec).

- 5 Found: C, 48.69; H, 7.35; N, 11.12%.  $C_{10}H_{18}N_2O_5$  requires C, 48.77; H, 7.37; N, 11.38%.

Description 11

- 10 N-tert-Butoxycarbonyl-β-[(2-pyrrolidinoethyl)amide]-  
(S)-aspartic acid methylamide (D11)

15



- 20 To a solution of N-tert-butoxycarbonyl-(S)-aspartic acid methylamide (D10) (5g) in dichloromethane (50 ml) at 0°C was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (4.74g) and 1-hydroxybenzotriazole (3.34g). After 10 mins N-(2-aminoethyl)pyrrolidine (2.82g) was added dropwise, and the solution was stirred at 0°C for 2h
- 25 and then at room temperature overnight. The reaction mixture was washed with sodium bicarbonate solution, water, and dried ( $Na_2SO_4$ ), and then evaporated to dryness in vacuo to give the title compound (D11) (1.0g).


- 30  $\delta$  ( $CDCl_3$ ): 1.42 (9H, s), 1.9 (4H, m), 2.5-2.9 (8H, m), 2.82 (3H, d,  $J=5$ Hz), 3.38 (2H, q,  $J=5$ Hz), 4.5 (1H, m), 6.21 (1H, m), 6.75 (1H, m) and 7.02 (1H, m).

SUBSTITUTE SHEET

- 40 -

Description 12

N-[N-((R)-1-Dibenzyloxyphosphinylpropyl)-(S)-leucyl]-β-  
[(2-pyrrolidinoethyl)amide]-(S)-aspartic acid methylamide  
 5 (D12)




This compound was prepared from N-(1-(R)-dibenzyloxy-  
 phosphinylpropyl)-(S)-leucine (D3A) and  
 15 β-[(2-pyrrolidinoethyl)amide]-(S)-aspartic acid  
 methylamide (prepared from (D11) by reaction with  
 trifluoroacetic acid by the procedure described for (D5))  
 following the method of Description 11, m.p. 110-118°C  
 (48% yield).

20 δ (CDCl<sub>3</sub>): 0.85 (6H, t, J=5Hz), 1.05 (3H, t, J=7Hz), 1.4 (3H, m),  
 1.6 (3H, m), 1.85 (approx. 6H, m), 2.6-2.85 (approx. 10H, m),  
 3.3 (1H, m), 3.45 (1H, m), 3.65 (1H, m), 4.85 (1H, m), 5.0 (4H, m),  
 7.45 (10H, m), 7.5 (1H, m) and 8.2 (1H, d, J=7Hz).

Description 13

N<sup>α</sup>-tert-Butoxycarbonyl-N<sup>ω</sup>-nitro-(S)-arginine methylamide  
 30 (D13)




SUBSTITUTE SHEET

- 41 -

$N^{\alpha}$ -tert-Butoxycarbonyl- $N^{\omega}$ -nitro-(S)-arginine (3g, 9.4 mmol), 1-hydroxybenzotriazole (2.88g, 18.8 mmol) and methylamine hydrochloride (1.26g, 18.7 mmol) were dissolved in dry dimethylformamide (50 ml) and cooled in an ice-salt bath to  $-10^{\circ}\text{C}$ . Diisopropylethylamine (3.3 ml, 18.78 mmol) was added followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (2.76g, 14.4 mmol). After 1h, at  $0^{\circ}\text{C}$  the reaction mixture was stirred for 18h at room temperature when t.l.c. [(CHCl<sub>3</sub>:MeOH:AcOH) (10:2:1) v/v] showed the reaction to be complete. After evaporation to dryness the solid was dissolved in water and applied to a column of Dowex 50W-X8 (ammonium form). This was eluted with water and eluant containing UV absorbing material was collected, concentrated and then shaken with Amberlite IRA-401 (acetate form) for 1h. The resin was collected and washed with water. The filtrate and washings were combined and lyophilised to give the product (D13) as a chromatographically pure white solid (2.6g, 84%).  
 Observed FAB (M+H)<sup>+</sup> 333. C<sub>18</sub>H<sub>24</sub>N<sub>6</sub>O<sub>5</sub> requires M 332.

#### Description 14

$N^{\alpha}$ -[N-((R)-1-Dibenzoyloxyphosphinylpropyl)-(S)-leucyl]- $N^{\omega}$ -nitro-(S)-arginine methylamide (D14)



**SUBSTITUTE SHEET**


- 42 -

$N^{\alpha}$ -tert-Butoxycarbonyl- $N^{\omega}$ -nitro-(S)-arginine methylamide (D13) (0.142g, 0.43 mmol) was treated with 95% trifluoroacetic acid in water (5 ml) for 0.5h at 0°C. Excess acid was removed under reduced pressure and the residue twice evaporated with dry toluene. The residue was dissolved in dry dimethylformamide (2 ml) and the pH adjusted to 8-9 by the addition of diisopropylethylamine. This was added to a solution of N-(1-(R)-dibenzoyloxyphosphinylpropyl)-(S)-leucine (D3A) (0.15g, 0.35 mmol) and 1-hydroxybenzotriazole (0.095g, 0.62 mmol) in dimethylformamide (5 ml). The mixture was cooled to -10 to -15°C and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.08g, 0.42 mmol) added. The reaction mixture was allowed to warm to room temperature and stirred for 18h. The mixture was then evaporated to dryness and purified by silica gel chromatography [(MeOH:CHCl<sub>3</sub>) (1:9) v/v]. The product (D14) was obtained as a pale yellow foam. (0.16g, 71%).

Observed FAB (M+H)<sup>+</sup> 648. C<sub>30</sub>H<sub>46</sub>N<sub>7</sub>O<sub>7</sub>P requires M 647.

Description 15

$N^{\alpha}$ -tert-Butoxycarbonyl-(R)- $\beta$ -(4-pyridyl)alanine (D15A) and  
 $N^{\alpha}$ -tert-butoxycarbonyl-(S)- $\beta$ -(4-pyridyl)alanine (D15B)



SUBSTITUTE SHEET

- 43 -

Crude racemic  $\beta$ -(4-pyridyl)alanine dihydrochloride<sup>1</sup> (0.88g, 3.66 mmol) was dissolved in water (30 ml) and solid  $\text{NaHCO}_3$  (1.51g) added. When dissolved, dioxan (30 ml) was added and the mixture cooled in an ice-salt bath to 0°C. Di-tert-butyl dicarbonate (1.5g, 6.9 mmol) as a solution in dioxan (20 ml) was added and after 1h at 0-4°C, the mixture was stirred for 18h at room temperature. The reaction mixture was evaporated to dryness and a mixture of ethyl acetate, water and acetic acid (5:1:1, v/v) added. The precipitated solid was filtered off and the filtrate evaporated in vacuo. The residue was triturated with several portions of hot ethanol. When cool, the extracts were combined and evaporated to dryness. This process was repeated until the solid residue redissolved readily in ethanol. Evaporation of this solution gave the title compound (D15) as a racemic mixture, contaminated with sodium acetate. This was used without further purification.

20


<sup>1</sup>R.L. Bixler and C. Niemann, J. Org. Chem., 23, 575 (1958).

#### Description 16

25

N $\alpha$ -tert-Butoxycarbonyl-(R)- $\beta$ -(4-pyridyl)alanine methylamide (D16A) and N $\alpha$ -tert-butoxycarbonyl-(S)- $\beta$ -(4-pyridyl)alanine methylamide (D16B)

30



35

SUBSTITUTE SHEET


- 44 -

Crude racemic derivative (D15) (3.66 mmol) was dissolved in dry dimethylformamide (30 ml) and 1-hydroxybenzo-triazole (1.13g, 7.38 mmol) and methylamine hydrochloride (0.5g, 7.40 mmol) added. The mixture was cooled to  $-10^{\circ}\text{C}$  in an ice-salt bath and diisopropylethylamine (1.3 ml, 7.5 mmol) added. After 5 minutes, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.7g, 8.9 mmol) was added and after stirring for 1h at  $-5^{\circ}\text{C}$ , the mixture was stirred overnight at room temperature. After evaporation to dryness, dichloromethane (50 ml) was added and then extracted with several portions (3x15 ml) of sat. aq.  $\text{NaHCO}_3$ . The organic phase was dried over anhydrous magnesium sulphate, filtered and the solvent removed in vacuo. The residue was purified by silica gel chromatography [(MeOH: $\text{CHCl}_3$ ) (1:9) v/v] to give the racemic title compound (D16) as a white solid (0.91g).

Observed FAB  $(\text{M}+\text{H})^+$  280.  $\text{C}_{14}\text{H}_{21}\text{N}_3\text{O}_3$  requires M 279.

#### 20 Description 17

$\text{N}^{\alpha}$ -tert-Butoxycarbonyl-(R)- $\beta$ -(4-piperidyl)alanine methylamide (D17A) and  $\text{N}^{\alpha}$ -tert-butoxycarbonyl-(S)- $\beta$ -(4-piperidyl)alanine methylamide (D17B)



The mixture of isomers of amide (D16) (0.5g, 1.79 mmol) was dissolved in glacial acetic acid (45 ml) and degassed


SUBSTITUTE SHEET

- 45 -

under reduced pressure. A suspension of Adam's catalyst (0.2g) in glacial acetic acid (5 ml) was added and the mixture hydrogenated for 22h at atmospheric pressure. The reaction mixture was filtered through Kieselguhr and the solvent removed in vacuo to give the racemic product (D17) as a chromatographically pure oil (0.51g).

### Description 18

10 N<sup>α</sup>-tert-Butoxycarbonyl-(R)-β-(4-(N-benzyloxycarbonyl)-piperidyl)alanine methylamide (D18A) and N<sup>α</sup>-tert-butoxycarbonyl-(S)-β-(4-(N-benzyloxycarbonyl)piperidyl)alanine methylamide (D18B)



20

Isomer mixture (D17) (0.51g, 1.79 mmol) was dissolved in a dioxan/water mixture (2:1, 30 ml) and the pH adjusted to 7 by the addition of solid NaHCO<sub>3</sub>. The mixture was cooled to 0°C, a second portion of NaHCO<sub>3</sub> (0.17g, 2 mmol) added followed by the portionwise addition of benzylchloroformate (0.3 ml, 2.1 mmol). After 1h at 0°C, the mixture was stirred overnight at room temperature. After evaporation to dryness, the residue was taken up in ethyl acetate and extracted with 10% aq. citric acid (2x), sat. aq. NaHCO<sub>3</sub> (2x) and sat. aq. NaCl. The organic phase was dried (anhydrous MgSO<sub>4</sub>), filtered and the solvent removed in vacuo. The resultant oil was purified by

SUBSTITUTE SHEET

- 46 -

silica gel chromatography [(CH<sub>2</sub>Cl<sub>2</sub>:MeOH) (19:1)v/v] to give the racemic title compound (D18) as an oil which crystallised on standing under 60-80 light petroleum (0.68g, 91%), m.p. 130-131°C.


5

Observed FAB (M+H)<sup>+</sup> 420. C<sub>22</sub>H<sub>33</sub>N<sub>3</sub>O<sub>5</sub> requires M 419.

### Description 19

10 N<sup>α</sup>-[N-((R)-1-Dibenzoyloxyphosphinylpropyl)-(S)-leucyl]-(R)-β-(4-(N-benzoyloxycarbonyl)piperidyl)alanine methylamide (D19A) and N<sup>α</sup>-[N-((R)-1-dibenzoyloxyphosphinylpropyl)-(S)-leucyl]-(S)-β-(4-(N-benzoyloxycarbonyl)piperidyl)alanine methylamide (D19B)

15



20

The protected amide isomer mixture (D18) (0.19g, 0.45 mmol) was treated with 95% trifluoroacetic acid in water (5 ml) for 0.5h at 0°C. Excess acid was removed under reduced pressure and the oily residue evaporated twice with dry toluene. The residue was dissolved in dry dimethylformamide (2 ml) and the pH adjusted to 8-9 by the addition of diisopropylethylamine. This was added to a solution of N-(1-(R)-dibenzoyloxyphosphinylpropyl)-(S)-leucine (D3A) (0.15g, 0.35 mmol) and 1-hydroxybenzo-triazole (0.11g, 0.7 mmol) in dimethylformamide (5 ml). The mixture was cooled to -10°C and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride

30

**SUBSTITUTE SHEET**



- 47 -


(0.1g, 0.52 mmol) added. The mixture was allowed to warm to room temperature and then stirred for 18h. The reaction mixture was evaporated to dryness in vacuo and the residue redissolved in dichloromethane. This was  
5 extracted with 10% aq. citric acid, sat. aq.  $\text{NaHCO}_3$  (2x) sat. aq.  $\text{NaCl}$  and then dried over anhydrous magnesium sulphate. Evaporation in vacuo gave the title compound isomer mixture (D19) as an oil which was purified by silica gel chromatography [ $(\text{CH}_2\text{Cl}_2:\text{MeOH}) (9:1)$ ].

10

Description 20

$\text{N}^\alpha$ -tert-Butoxycarbonyl- $\text{N}^\epsilon$ -benzyloxycarbonyl-(S)-ornithine methylamide (D20)

15



20

A solution of  $\text{N}^\alpha$ -tert-butoxycarbonyl- $\text{N}^\epsilon$ -benzyloxycarbonyl-(S)-ornithine (1.5g, 0.004 mol) in anhydrous dichloromethane (60 ml) maintained at  $0^\circ\text{C}$  was sequentially  
25 treated with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.94g) and 1-hydroxybenzotriazole (0.66g) and then left stirring for 0.5h. Methylamine (excess) was bubbled through, flushed with nitrogen and the solution extracted with dilute citric acid (40 ml) and brine (40  
30 ml). The organic phase was dried and evaporated to yield a viscous oil. Purification by flash chromatography [2% methanol in ethyl acetate] afforded the title compound (D20) as a white solid (1.2g).

SUBSTITUTE SHEET


- 48 -

Observed FAB  $(M+H)^+$  380.  $C_{19}H_{29}N_3O_5$  requires  $M$  379.

### Description 21

- 5  $N^\alpha$ -Benzyloxycarbonyl-(S)-ornithine methylamide,  
trifluoroacetate salt (D21)

10



15 A solution of the amide (D20) (0.14g) in dichloromethane  
 (5 ml) maintained at 0°C was treated with trifluoroacetic  
 acid (2 ml). The solution was left stirring at room  
 temperature for 2h, then solvent evaporated in vacuo to  
 afford crude title compound (D21) as an oil. This was  
 used as such without further purification.


20

### Description 22

$N^\alpha$ -[N-((R)-1-Dibenzoyloxyphosphinylpropyl)-(S)-leucyl]- $N^\epsilon$ -  
benzyloxycarbonyl-(S)-ornithine methylamide (D22)

25

30



SUBSTITUTE SHEET


- 49 -

A stirred solution of N-(1-(R)-dibenzoyloxyphosphinylpropyl)-(S)-leucine (D3A) (0.142g) in anhydrous dichloromethane (15 ml) maintained at 0°C was treated with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.07g) and 1-hydroxybenzotriazole (0.049g). After 0.5h, the mixture was sequentially treated with crude salt (D21) and N,N-diisopropylethylamine (0.095g) and then left stirring at room temperature for 18h. The solution was then washed with 1M aq. citric acid (10 ml), sat. aq. NaHCO<sub>3</sub> (10 ml) and sat. aq. NaCl (10 ml). The organic fraction was dried and evaporated in vacuo to yield an oil. Purification by flash chromatography (5% methanol in chloroform) afforded the title compound (D22) as a white foam (0.095g).

Observed FAB (M+H)<sup>+</sup> 695. C<sub>37</sub>H<sub>51</sub>N<sub>4</sub>O<sub>7</sub>P requires M 694.

#### Description 23

N<sup>α</sup>-tert-Butoxycarbonyl-N<sup>ε</sup>-dimethyl-(S)-lysine methylamide (D23)



A solution of the amide (D4) (0.8g) in methanol (100 ml) was treated with 5% palladium on charcoal (1g). The suspension was diluted with 38% aqueous formaldehyde solution (6 ml) and hydrogenated at atmospheric pressure and ambient temperature for 48h. A further aliquot of catalyst (0.5g) and formaldehyde (3 ml) was added and

**SUBSTITUTE SHEET**

- 50 -

hydrogenation continued for a further 24h. The solution was filtered through Kieselguhr, solvent evaporated in vacuo and the residue purified by flash chromatography [(CHCl<sub>3</sub>:MeOH:NH<sub>3</sub>) (12:2:1) v/v] to afford the title  
5 compound (D23) (0.29g).


Observed M<sup>+</sup> 287. C<sub>14</sub>H<sub>29</sub>N<sub>3</sub>O<sub>3</sub> requires M 287.

Description 24

10

N<sup>ε</sup>-Dimethyl-(S)-lysine methylamide, trifluoroacetate salt (D24)

15




20 A stirred solution of the amine (D23) (0.11g) maintained at 0°C in dichloromethane (5 ml) was treated with trifluoroacetic acid (2 ml). The solution was stirred for 1h, then solvent evaporated at reduced pressure to afford crude title compound (D24) as a clear oil. This was used  
25 as such without further purification.

SUBSTITUTE SHEET

- 51 -

Description 25

$N^{\alpha}$ -[N-((R)-1-Dibenzyloxyphosphinylpropyl)-(S)-leucyl]-N<sup>E</sup>-dimethyl-(S)-lysine methylamide (D25)



A stirred solution of N-(1-(R)-dibenzyloxyphosphinylpropyl)-(S)-leucine (D3A) (0.132g) in anhydrous dichloromethane (20 ml) was treated sequentially with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.066g) and 1-hydroxybenzotriazole (0.042g). The mixture was left stirring for 0.5h, treated with amine salt (D24) and N,N-diisopropylethylamine (0.148g) and stirring continued for 4h at room temperature. The mixture was washed with water (2x10 ml), sat. aq. NaHCO<sub>3</sub> (20 ml), dried over anhydrous magnesium sulphate and evaporated in vacuo to give a pale yellow oil. Purification by flash chromatography [(CHCl<sub>3</sub>:MeOH:NH<sub>3</sub>) (15:2:0.5)v/v] afforded the title compound (D25) as a white foam (0.11g).


Observed FAB (M+H)<sup>+</sup> 603. C<sub>32</sub>H<sub>51</sub>N<sub>4</sub>O<sub>5</sub>P requires M 602.

SUBSTITUTE SHEET

- 52 -

Description 26N<sup>α</sup>-tert-Butoxycarbonyl-N<sup>ε</sup>-dimethyl-(S)-ornithine  
methanamide (D26)

5



10


The title compound (D26) was prepared following the procedure described for the synthesis of N<sup>α</sup>-tert-butoxycarbonyl-N<sup>ε</sup>-dimethyl-(S)-lysine (D23) (yield: 69%).

15

Observed FAB (M+H)<sup>+</sup> 274. C<sub>13</sub>H<sub>27</sub>N<sub>3</sub>O<sub>3</sub> requires M 273.

Description 27N<sup>ε</sup>-Dimethyl-(S)-ornithine methanamide, trifluoroacetate  
salt (D27)

25



The title compound (D27) was prepared following the procedure described for the synthesis of N<sup>ε</sup>-dimethyl-(S)-lysine methanamide, trifluoroacetate salt (D24). The title compound (D27) was used without any formal purification.


30

SUBSTITUTE SHEET

- 53 -

Description 28

N<sup>α</sup>-[N-((R)-1-Dibenzyloxyphosphinylpropyl)-(S)-leucyl]-N<sup>ε</sup>-dimethyl-(S)-ornithine methylamide (D28)




The title compound (D28) was prepared following the procedure described for the synthesis of the dibenzyl ester (D25). (Yield: 56%).

Observed FAB (M+H)<sup>+</sup> 589. C<sub>31</sub>H<sub>49</sub>N<sub>4</sub>O<sub>5</sub>P requires M 588.

Description 29

(R)-2-Hydroxy-4-methylpentanoic acid (D29)



The title compound was prepared by modification of the method of G. Iwasaki *et al*, Chem. Pharm. Bull. 1989, 37(2), 280. A solution of sodium nitrite (33.8g) in water (100 ml) was added dropwise over 1.75h to a stirred

SUBSTITUTE SHEET


- 54 -

solution of D-leucine (20g, 0.15 mol) in 3N sulphuric acid (700 ml) and 50% aqueous acetic acid (500 ml) at 92-98°C. The mixture was heated for a further 3h at 98-99°C, then cooled and extracted with diethyl ether (4x250 ml). The combined organic layers were dried with anhydrous magnesium sulphate, filtered and evaporated to dryness to give the title compound (D29) as a pale yellow solid (18.91g, 94%). A sample was recrystallized from  $\text{CHCl}_3$ /pentane as white needles, m.p. 77.5-79°C.

$[\alpha]_D^{22} = 26.41$  (c=0.98 1N NaOH).

#### Description 30

Methyl (R)-2-hydroxy-4-methylpentanoate (D30)




A mixture of acid (D29) (3.97g, 0.03 mol) in methanol (100 ml) and 1N ethereal HCl (10 ml) was maintained at ambient temperature for 5 days. After evaporation to dryness and purification by chromatography on silica gel with diethyl ether as eluant the title compound (D30) was obtained as a pale yellow oil (3.51g, 80%) and was carried forward without further purification.

**SUBSTITUTE SHEET**



- 55 -

Description 31N-(1-(S)-Diethoxyphosphinylpropyl)-(S)-leucine methyl ester (D31)

The alcohol (D31) (0.696g, 0.0048 mol) in dichloromethane (10 ml) was cooled to  $-60^{\circ}\text{C}$  and then 2,6-lutidine (0.68 ml) followed by trifluoromethanesulphonic anhydride (0.92 ml) were added. After allowing to warm to  $0^{\circ}\text{C}$  a solution of (S)-1-aminopropylphosphonic acid, diethyl ester<sup>1</sup> (0.93g, 0.0048 mol) in dichloromethane (10 ml) was added, followed by proton sponge (1.02g). The mixture was stirred for 4 days in the dark under  $\text{N}_2$  and then filtered, the solid washed with chloroform and the filtrate washed with 10% citric acid (x2) followed by water. The organic layer was dried with anhydrous magnesium sulphate, filtered and evaporated to give the crude product as a red oil. Purification by column chromatography (first silica gel with gradient elution 0-6%  $\text{MeOH}/\text{CHCl}_3$ , then silica gel with gradient elution 0-2%  $\text{MeOH}/\text{EtOAc}$ ) gave the title compound (D31) as a pale yellow oil (0.48g, 33%).

Observed  $\text{M}^+$  323.1862.  $\text{C}_{14}\text{H}_{30}\text{NO}_5\text{P}$  requires 323.1858.

Other physical properties in accord with the literature<sup>1</sup>

<sup>1</sup> EP-A-0 401 963

SUBSTITUTE SHEET


- 56 -

Description 32

N<sup>α</sup>-[N-((S)-Diethoxyphosphinylpropyl)-(S)-leucyl]-N<sup>ε</sup>-benzyloxycarbonyl-(S)-lysine methyl amide (D32)

5

10



15

20

25

30

N-(1-(S)-Diethoxyphosphinylpropyl)-(S)-leucine<sup>1</sup> was prepared from the corresponding methyl ester (D31) by standard base hydrolysis. A solution of this acid (0.25g, 0.00081 mol) in dichloromethane (9 ml) was cooled to 0°C under N<sub>2</sub> and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.17g) then 1-hydroxybenzotriazole (0.12g) were added and the mixture stirred for 1h at this temperature. N<sup>ε</sup>-Benzyloxycarbonyl-(S)-lysine methylamide trifluoroacetate (D5) (from 0.0097 mol of the corresponding N<sup>α</sup>-tert-butoxycarbonyl derivative (D4)) in dichloromethane (5 ml) was added followed by diisopropylethylamine (0.35 ml) and the mixture stirred at room temperature overnight. After dilution with chloroform (20 ml) the mixture was washed with 10% citric acid (x2) and water. The organic layer was dried (anhydrous magnesium sulphate) and volatile material evaporated in vacuo to give a colourless gum. Purification by chromatography on silica gel (gradient elution 0-5% MeOH/EtOAc) gave the product (D32) as a colourless gum (0.36g, 76%).

Observed M<sup>+</sup> 584.3346. C<sub>28</sub>H<sub>49</sub>N<sub>4</sub>O<sub>7</sub>P requires 584.3339.

<sup>1</sup> EP-A-0 401 963

SUBSTITUTE SHEET


- 57 -

Description 33

N<sup>α</sup>-[N-((S)-1-Diethoxyphosphinylpropyl)-(S)-leucyl]-(S)-lysine methylamide (D33)

5

10




N<sup>α</sup>-[N-((S)-1-Diethoxyphosphinylpropyl)-(S)-leucyl]-N<sup>ε</sup>-benzyloxycarbonyl-(S)-lysine methylamide (D32) (0.18g, 0.0003 mol) in methanol (25 ml) with 10% palladium on charcoal (0.2g) was hydrogenated at atmospheric pressure overnight. After filtration through Kieselguhr and evaporation to dryness the title compound (D33) was obtained as a clear gum.

20 Observed M<sup>+</sup> 450.2982. C<sub>20</sub>H<sub>43</sub>N<sub>4</sub>O<sub>5</sub>P requires 450.2972.

Description 34

N<sup>ε</sup>-Benzyloxycarbonyl-N<sup>α</sup>-tert-butoxycarbonyl-(S)-lysine 2-hydroxyethylamide (D34)

30



SUBSTITUTE SHEET


- 58 -

A solution of N<sup>ε</sup>-benzyloxycarbonyl-N<sup>α</sup>-tert-butoxycarbonyl-(S)-lysine (5g, 0.0132 mol) in dichloromethane (50 ml) was cooled to 0°C and 1-hydroxybenzotriazole (1.78g) followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (2.52g) were added. The mixture was stirred at 0°C for 1h and then ethanolamine (0.88g, 0.0144 mol) added in one portion. The solution was stirred overnight at room temperature, washed with water (2x30 ml), saturated sodium bicarbonate (30 ml) and finally water (30 ml). The organic layer was dried with anhydrous magnesium sulphate, filtered and evaporated to dryness to give the product (D34) as a clear gum (5.44g, 97%) which was used without further purification.

Observed M<sup>+</sup> 423.2365. C<sub>21</sub>H<sub>33</sub>N<sub>3</sub>O<sub>6</sub> requires 423.2369.

#### Description 35

N<sup>ε</sup>-Benzyloxycarbonyl-(S)-lysine 2-hydroxyethylamide,  
trifluoroacetate salt (D35)



Trifluoroacetic acid (30 ml) was added to a stirred solution of the lysine derivative (D34) (2.64g, 0.0062 mol) in dichloromethane (50 ml) at 0°C. After 3h stirring at ice-bath temperature volatile material was removed

SUBSTITUTE SHEET


- 59 -

under reduced pressure to give the crude product (D35) in quantitative yield. This was used in subsequent steps without further purification.

5 Observed FAB (M+H)<sup>+</sup> 324. C<sub>16</sub>H<sub>25</sub>N<sub>3</sub>O<sub>4</sub> requires M 323.

### Description 36

10 N<sup>α</sup>-[N-((R)-1-Dibenzoyloxyphosphinylpropyl)-(S)-leucyl]-(S)-N<sup>ε</sup>-benzyloxycarbonyl-lysine 2-hydroxyethylamide (D36)



A solution of N-((R)-1-dibenzoyloxyphosphinylpropyl)-(S)-leucine (D3A) (1.61g, 0.0037 mol) in dichloromethane  
 20 (60 ml) was cooled to 0°C and 1-hydroxybenzotriazole (0.78g, 0.0058 mol) was added followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.09g, 0.0057 mol). The mixture was stirred for 1h at ice-bath temperature and then a solution of the trifluoroacetate  
 25 salt (D35) (1.2 equivalents) in dichloromethane (15 ml) was added followed by diisopropylethylamine (3.36g) to ensure neutralization of excess trifluoroacetic acid. After stirring overnight at room temperature the reaction mixture was washed with 10% aqueous citric acid (2x20 ml),  
 30 water (20 ml), saturated sodium bicarbonate (2x20 ml) and finally water. The organic layer was dried (anhydrous magnesium sulphate) filtered and evaporated to dryness. The residue was chromatographed on silica gel with 1:1

**SUBSTITUTE SHEET**

- 60 -

increasing percentage of methanol (to 10%). Further purification on silica gel with a gradient of 0-4% MeOH/CHCl<sub>3</sub> gave the title compound (D36) as a clear gum (0.83g, 30%).


5

Observed M<sup>+</sup> 738. C<sub>39</sub>H<sub>55</sub>N<sub>4</sub>O<sub>8</sub>P requires M 738.

### Description 37

10 N<sup>α</sup>-[N-((S)-1-Dibenzoyloxyphosphinylpropyl)-(S)-leucyl]-(S)-N<sup>ε</sup>-benzyloxycarbonyl-lysine 2-hydroxyethylamide (D37)

15



20

The title compound (D37) (1.035g) was prepared from N-((S)-1-dibenzoyloxyphosphinylpropyl)-(S)-leucine (D3B) (0.67g, 0.0015 mol) and the trifluoroacetate salt (D35) by the method given in Description 36.

25


Observed FAB (M+H)<sup>+</sup> 739. C<sub>39</sub>H<sub>55</sub>N<sub>4</sub>O<sub>8</sub>P requires M 738.

- 61 -

Description 38

N<sup>α</sup>-[(S)-tert-Butoxycarbonyl-leucyl]-N<sup>ε</sup>-benzyloxycarbonyl-  
(S)-lysine methylamide (D38)

5



10

N-tert-Butyloxycarbonyl-(S)-leucine (25g, 0.11 mol) was dissolved in dichloromethane (250 ml) and cooled to 0°C. 1,1'-Carbonyldiimidazole (18g, 0.113 mol) was added and the mixture left stirring at 0°C for 0.5h. The solution was allowed to warm to room temperature for 15 mins and then recooled to 0°C.

N<sup>ε</sup>-Benzyloxycarbonyl-(S)-lysine methylamide trifluoroacetate salt (D5) (47g, 0.118 mol) in dichloromethane (150 ml) was added followed by the immediate addition of diisopropylethylamine (30.5g, 0.236 mol). The reaction mixture was left stirring overnight at room temperature and then treated with water and extracted with chloroform. The combined organic layers were washed with dilute hydrochloric acid (2x100 ml), water (2x100 ml), aqueous sodium carbonate (3x100 ml) and brine. The organic layer was dried with anhydrous magnesium sulphate and evaporated to dryness to give the title compound (D38) (50g, 93%) which was used without further purification.

30

Observed (M+H)<sup>+</sup> 507. C<sub>26</sub>H<sub>42</sub>N<sub>4</sub>O<sub>6</sub> requires M 506.

SUBSTITUTE SHEET


- 62 -

Description 39

N<sup>α</sup>-[(S)-Leucyl]-N<sup>ε</sup>-benzyloxycarbonyl-(S)-lysine  
methanamide (D39)

5

10



A cooled solution of the amide (D38) (50g, 0.099 mol) in dichloromethane (150 ml) was treated with trifluoroacetic acid (150 ml). After 3h the solvent was evaporated under reduced pressure. The resulting oil was dissolved in methanol and acidified with dilute hydrochloric acid to give the hydrochloride salt. Water was added and non-basic organic material extracted out with ethyl acetate (2x200 ml). The aqueous layer was basified to pH 8-9 with 10% sodium hydroxide and then extracted with ethyl acetate (3x150 ml). These combined organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated to dryness to give the title compound (D39) (20g, 50%) as a white solid.

Observed (M+H)<sup>+</sup> 407. C<sub>21</sub>H<sub>34</sub>N<sub>4</sub>O<sub>4</sub> requires M 406.


SUBSTITUTE SHEET



- 63 -

Description 40

$N^{\alpha}$ -[N-((R)-1-Dibenzyloxyphosphinylpropyl)-(S)-leucyl]- $N^{\epsilon}$ -benzyloxycarbonyl-(S)-lysine methylamide and  $N^{\alpha}$ -[N-((S)-1-Dibenzyloxyphosphinylpropyl)-(S)-leucyl]-(S)- $N^{\epsilon}$ -benzyloxycarbonyl-lysine methylamide (D40)



Dibenzyl ((1-trifluoromethanesulphonyloxy)propyl)-phosphonate (D2) (4.4g, 0.0098 mol) was dissolved in dry  
 15 dichloromethane (20 ml).  $N^{\alpha}$ -[(S)-Leucyl]- $N^{\epsilon}$ -benzyloxycarbonyl-(S)-lysine methylamide (D39) (4.0g, 0.0098 mol) and Proton Sponge (2.0g, 0.0098 mol) were added to the solution and the reaction mixture was stirred in the dark at room temperature for 10 days.

20 The solution was diluted further with chloroform, washed with 10% citric acid (2x50 ml) and water (3x50 ml), dried (anhydrous  $MgSO_4$ ) and evaporated to dryness to give an orange oil. This was purified by column chromatography  
 25 (silica gel, 2% MeOH/EtOAc) to give the mixture of title compounds (D40) (2.55g, 35%) as a clear oil.

Observed  $(M+H)^+$  709.  $C_{38}H_{53}N_4O_7P$  requires  $M$  708.

30

SUBSTITUTE SHEET


- 64 -

Description 41

N<sup>α</sup>-[N-((S)-1-Dibenzyloxyphosphinylpropyl)-(S)-leucyl]-N<sup>ω</sup>-nitro-(S)-arginine methylamide (D41)

5

10




The title compound (D41) (0.72g, 74%) was prepared from N<sup>α</sup>-tert-butoxycarbonyl-N<sup>ω</sup>-nitro-(S)-arginine methylamide (D13) (0.6g, 0.0018 mol) and N-((S)-1-dibenzyloxyphosphinylpropyl)-(S)-leucine (D3B) (0.633g, 0.0014 mol) by the method described in Description 14 with the exception that dichloromethane was used as reaction solvent with sufficient dimethylformamide to effect solution.

Description 42

N-((R)-1-Dibenzyloxyphosphinylethyl)-(S)-leucine (D42A)  
and N-((S)-1-dibenzyloxyphosphinylethyl)-(S)-leucine (D42B)

30



SUBSTITUTE SHEET


- 65 -

The title mixture of diastereoisomers (D42) was prepared analogously to the method in Description 3, Method B, as a white solid.

5 Observed FAB  $(M+H)^+$  420.  $C_{22}H_{30}NO_5P$  requires  $M$  419.

#### Description 43

10  $N^\alpha$ -[N-((R)-1-Dibenzyloxylphosphinylethyl)-(S)-leucyl]-(S)- $N^\epsilon$ -benzyloxycarbonyl-lysine methylamide (D43A) and  $N^\alpha$ -[N-((S)-1-Dibenzyloxylphosphinylethyl)-(S)-leucyl]-(S)- $N^\epsilon$ -benzyloxycarbonyl-lysine methylamide (D43B)



20 The title compound (D43) was obtained as a clear oil (1.0g, 63%) from the acid (D42) (1.0g, 0.002 mol) following the general method of Description 6.

Observed FAB  $(M+H)^+$  695.  $C_{37}H_{51}N_4O_7P$  requires  $M$  694.

25

**SUBSTITUTE SHEET**


- 66 -

Example 1

N<sup>α</sup>-[N-((R)-1-Phosphonopropyl)-(S)-leucyl]-(S)-lysine  
methanamide (E1)

5

10



15 The dibenzyl ester (D6) (0.105g, 0.16 mmol) was dissolved in ethanol (40 ml) and hydrogenated over 10% palladium on charcoal at atmospheric pressure. The solution was filtered through Kieselguhr and solvent evaporated in vacuo to give the title compound (E1) (0.01g).

20

Observed FAB (M+H)<sup>+</sup> 395. C<sub>16</sub>H<sub>35</sub>O<sub>5</sub>N<sub>4</sub>P requires M 394.

δ (CDCl<sub>3</sub>/CD<sub>3</sub>OD): 0.95 (6H,dd), 1.08 (3H,t), 1.4-2.0 (9H,m), 2.65 (1H,m), 2.75 (3H,s), 2.92 (2H,m), 3.45

25 (2H,m), 4.18 (1H,m), 4.4 (1H,m).

SUBSTITUTE SHEET


- 67 -

Example 2

N<sup>α</sup>-[N-((R)-1-Phosphonopropyl)-(S)-leucyl]-N<sup>ε</sup>-glycyl-  
(S)-lysine methylamide (E2)

5

10



15 The dibenzyl ester (D9) (0.43g) was dissolved in ethanol (60 ml) and hydrogenated over 10% palladium on charcoal at atmospheric pressure. The solution was filtered through Kieselguhr and solvent evaporated in vacuo to give the title compound (E2) (0.059g).

20

Observed FAB (M+H)<sup>+</sup> 452. C<sub>18</sub>H<sub>38</sub>O<sub>6</sub>N<sub>5</sub>P requires M 451.


δ (CD<sub>3</sub>OD): 0.78-0.95 (9H,m), 1.19-1.9 (11H,m), 2.31 (1H,m), 2.62 (3H,s), 3.05-3.25 (2H,m), 3.30-3.65 (2H,m),  
 25 3.83-3.92 (1H,bt), 4.15-4.3 (1H,t).

SUBSTITUTE SHEET

- 68 -

Example 3

N-[N-((R)-1-Phosphonopropyl)-(S)-leucyl]-β-[(2-pyrrolidinoethyl)amide]-(S)-aspartic acid methylamide (E3)




This compound was prepared from N-[N-[(R)-dibenzoyloxyphosphinylpropyl]-(S)-leucine-β-[(2-pyrrolidinoethyl)-amide]]-(S)-aspartic acid methylamide (D12) by hydrogenation over 10% palladium on charcoal at atmospheric pressure. m.p. 130-135°C (95% yield).

δ (CD<sub>3</sub>OD): 1.0 (6H, t, J=6Hz), 1.1 (3H, t, J=7Hz), 1.55-1.8 (4H, m), 2.0 (1H, m), 2.15 (4H, m), 2.6-2.85 (6H, m), 3.3-3.75 (approx. 8H, m), 4.1 (1H, t, J=6Hz) and 4.75 (1H, t, J=5Hz).

Example 4

N<sup>α</sup>-[N-((R)-1-Phosphonopropyl)-(S)-leucyl]-(S)-arginine methylamide (E4)



SUBSTITUTE SHEET

- 69 -

The fully protected derivative (D14) was dissolved in a mixture of glacial acetic acid (40 ml) and water (10 ml) and hydrogenated over 10% palladium on charcoal catalyst for 18h at atmospheric pressure. The solution was  
 5 filtered through Kieselguhr and solvent evaporated in vacuo to give the title compound (E4) (0.085g).

Observed FAB (M+H)<sup>+</sup> 423. C<sub>16</sub>H<sub>35</sub>N<sub>6</sub>O<sub>5</sub>P requires M 422.


10  $\delta$  (CD<sub>3</sub>OD): 0.95 (6H, dd), 1.03 (3H, t), 1.5-1.94 (9H, m), 2.56 (1H, m), 2.72 (3H, s), 3.17 (2H, m), 4.02 (1H, t), 4.37 (1H, t).

#### Example 5

15

N <sup>$\alpha$</sup> -[N-((R)-1-Phosphonopropyl)-(S)-leucyl]-(R)- $\beta$ -(4-piperidyl)alanine methylamide (E5A) and  
N <sup>$\alpha$</sup> -[N-((R)-1-phosphonopropyl)-(S)-leucyl]-(S)- $\beta$ -(4-piperidyl)alanine methylamide (E5B)

20



25

The fully protected derivative (D19) (0.24g) was dissolved in ethanol (50 ml) and hydrogenated over 10% palladium on charcoal at atmospheric pressure. The solution was  
 30 filtered through Kieselguhr and solvent evaporated in vacuo. The residue was triturated with ether to remove slight impurities leaving the product (E5) as an off-white solid (0.13g).

**SUBSTITUTE SHEET**

- 70 -


Observed FAB  $(M+H)^+$  421.  $C_{18}H_{37}N_4O_5P$  requires  $M$  420.

$\delta$  ( $CD_3OD$ ): 0.95 (6H, dd), 1.02, 1.05 (3H, overlapping triplets), 1.4-2.0 (12H, m), 2.4-2.55 (1H, 2 overlapping m),  
 5 2.71 (3H, d), 2.81-3.03 (2H, m), 3.34 (4H, br m), 3.68-3.81 (1H, dt), 4.40 (1H, m).

### Example 6

10  $N^\alpha$ -[N-((R)-1-Phosphonopropyl)-(S)-leucyl]-(S)-ornithine methylamide (E6)

15



A solution of phosphonic diester (D22) (0.07g) in methanol  
 20 (20 ml) was treated with 5% palladium on charcoal. The suspension was hydrogenated at atmospheric pressure for 24h, filtered through Kieselguhr and solvent evaporated in vacuo. The residue was triturated with diethyl ether (5 ml) to give the title compound (E6) as a white solid  
 25 (0.03g), m.p. 165-169°C.

Observed FAB  $(M+H)^+$  381.  $C_{15}H_{33}N_4O_5P$  requires  $M$  380.

$\delta$  ( $CDCl_3/CD_3OD$ ): 1.0 (6H, dd), 1.12 (3H, t), 1.6-1.9 (8H, m),  
 30 2.05 (1H, m), 2.7 (1H, m), 2.75 (3H, s), 2.9 (2H, t), 4.42 (1H, m), 4.55 (1H, t).

The S,S,S diastereoisomer is prepared by a similar method.


**SUBSTITUTE SHEET**



- 71 -

Example 7

N<sup>α</sup>-[N-((R)-1-Phosphonopropyl)-(S)-leucyl]-N<sup>ε</sup>-dimethyl-(S)-lysine methylamide (E7)



A solution of phosphonic diester (D25) (0.75g) in methanol (20 ml) was treated with 5% palladium on charcoal (0.05g) and hydrogenated at atmospheric pressure for 24h. The solution was filtered through Kieselguhr and solvent evaporated in vacuo. The residue was triturated with diethyl ether (10 ml) to give the title compound (E7) as white solid (0.045g).

Observed FAB (M+H)<sup>+</sup> 423. C<sub>18</sub>H<sub>39</sub>N<sub>4</sub>O<sub>5</sub>P requires M 422.

δ (CD<sub>3</sub>OD): 1.0 (6H, dd), 1.1 (3H, t), 1.3-1.85 (10H, m), 2.0 (1H, m), 2.6 (1H, m), 2.75 (3H, s), 2.8 (6H, s), 3.05 (2H, t), 4.35 (2H, m).


- 72 -

Example 8

N<sup>α</sup>-[N-((R)-1-Phosphonopropyl)-(S)-leucyl]-N<sup>ε</sup>-dimethyl-(S)-ornithine methylamide (E8)

5

10



The title compound (E8) was prepared from the dibenzyl ester (D28) following the procedure described for the synthesis of N<sup>α</sup>-[N-((R)-1-phosphonopropyl)-(S)-leucyl]-N<sup>ε</sup>-dimethyl-(S)-lysine methylamide (E7). (Yield: 74%). m.p. 88.5-90°C.

Observed FAB (M+H)<sup>+</sup> 409. C<sub>17</sub>H<sub>37</sub>N<sub>4</sub>O<sub>5</sub>P requires M 408.


20

Example 9

N<sup>α</sup>-[N-((S)-1-Phosphonopropyl)-(S)-leucyl]- (S)-lysine methylamide, hydrobromide salt (E9)

25

30



SUBSTITUTE SHEET

- 73 -

Bromotrimethylsilane (0.48 ml, 12 equiv.) was added to a solution of the diethyl ester (D33) (0.14g, 0.0024 mol) in dry acetonitrile (10 ml) and stirred at room temperature for 3 days.

5

The resulting yellow solution was evaporated to dryness and treated with methanol/water. After evaporation and repeated treatment with methanol/water the product (E9) was obtained in quantitative yield as a pale orange foam.

10

Observed FAB  $(M+H)^+$  395.  $C_{16}H_{35}N_4O_5P$  requires  $M$  394.


$\delta$  ( $CD_3OD$ ): 1.01 (6H, dd), 1.18 (3H, t), 1.3-2.15 (11H, m), 2.74 (3H, s), 2.98 (2H, t), 3.19 (1H, m), 4.3 (1H, m), 4.42 (1H, t).

15

#### Example 10

$N^\alpha$ -[N-((R)-1-Phosphonopropyl)-(S)-leucyl]-(S)-lysine 2-hydroxyethylamide (E10)

20



25

A solution of the dibenzyl ester (D36) (0.8g, 0.0011 mol) in methanol (100 ml) with 10% palladium on charcoal was hydrogenated at atmospheric pressure overnight. After filtration through Kieselguhr and evaporation to dryness the residue was taken up in doubly distilled water, refiltered and freeze-dried to give the title compound (E10) as a white foam (0.39g, 85%).

**SUBSTITUTE SHEET**

- 74 -


Observed FAB  $(M+H)^+$  425.  $C_{17}H_{37}N_4O_6P$  requires M 424.

$\delta$  ( $CD_3OD$ ): 0.98 (6H, dd), 1.05 (3H, t), 1.3-2.05 (11H, overlapping m), 2.54 (1H, br m), 2.92 (2H, m), 3.3 (2H, m, overlaps  $CHD_2OD$  solvent signal), 3.6 (2H, t), 4.10 (1H, br m), 4.38 (1H, dd).

### Example 11

10  $N^\alpha$ -[N-((S)-1-Phosphonopropyl)-(S)-leucyl]-(S)-lysine 2-hydroxyethylamide (E11)

15



20 The title compound (E11) was obtained by atmospheric pressure hydrogenation of the dibenzyl ester (D37) by the method given in Example 10.

Observed FAB  $(M+H)^+$  425.  $C_{17}H_{37}N_4O_6P$  requires M 424.


25  $\delta$  ( $CD_3OD$ ): 0.97 (6H, dd), 1.12 (3H, t) 1.35-2.10 (11H, overlapping m), 2.46 (1H, m), 2.95 (2H, m), 3.32 (2H, m, overlaps  $CHD_2OD$  solvent signal), 3.53 (1H, m), 3.65 (2H, m), 4.49 (1H, m).

SUBSTITUTE SHEET

- 75 -

Example 12

N<sup>α</sup>-[N-((R)-1-Phosphonopropyl)-(S)-leucyl]-(S)-lysine  
methylamide and N<sup>α</sup>-[N-((S)-1-phosphonopropyl)-(S)-leucyl]-  
 5 (S)-lysine methylamide (E12)




The mixture of dibenzyl esters (D40) (2.55 g, 0.004 mol) in ethanol (100 ml) was hydrogenated over 10% palladium on charcoal at atmospheric pressure. The solution was  
 15 filtered through Kieselguhr and the solvent evaporated in vacuo to give the title compound (E12) as a white solid (1.0g, 71%).

Observed FAB (M+H)<sup>+</sup> 395. C<sub>16</sub>H<sub>35</sub>N<sub>4</sub>O<sub>5</sub>P requires M 394.

Example 13

N<sup>α</sup>-[N-((S)-1-Phosphonopropyl)-(S)-leucyl]-(S)-arginine  
methylamide (E13)



SUBSTITUTE SHEET

- 76 -

The title compound (E13) (0.5g, 90%) was prepared from the dibenzyl ester (D41) (0.633g, 0.014 mol) by the method of Example 4.


5 Observed FAB  $(M+H)^+$  423.  $C_{16}H_{35}N_6O_5P$  requires  $M$  422.

$\delta$  ( $CD_3OD$ ): 0.97 (6H, t), 1.10 (3H, t), 1.49-1.95 (9H, m),  
2.50 (1H, m), 3.21 (2H, m), 3.60 (1H, m), 4.94 (1H, m).

10 Example 14

$N^\alpha$ -[N-((R)-1-Phosphonopropyl)-(S)-leucyl]-(S)-homoarginine  
methanamide, disodium salt (E14A) and  $N^\alpha$ -[N-((S)-1-  
phosphonopropyl)-(S)-leucyl]-(S)-homoarginine methanamide,  
15 disodium salt (E14B)

20



The mixture of R,S,S and S,S,S isomers (E12) (34.5mg,  
0.087 mmol) in water (0.5 ml) was treated with sodium  
25 bicarbonate (44 mg, 6 equiv.) followed by 2-methyl-2-  
thiopseudourea sulphate (24.3 mg, 1 equiv.) and stirred at  
room temperature for 3h. Additional portions of sodium  
bicarbonate (8.5 mg) and 2-methyl-2-thiopseudourea (15 mg)  
were added and the mixture then heated at 70°C for 1.5h.  
30 Purification by reverse phase chromatography gave the  
title compound mixture of isomers (E14) as a white solid.

Observed FAB  $(M+H)^+$  481.  $C_{17}H_{35}N_6O_5PNa_2$  requires  $M$  480.


**SUBSTITUTE SHEET**

- 77 -

Example 15

- $N^{\alpha}$ -[N-((R)-1-Phosphonopropyl)-(S)-leucyl]-(S)- $N^{\epsilon}$ -(2-  
imidazolinyl)-lysine methylamide, disodium salt (E15A) and  
 5  $N^{\alpha}$ -[N-((S)-1-phosphonopropyl)-(S)-leucyl]-(S)- $N^{\epsilon}$ -(2-  
imidazolinyl)-lysine methylamide, disodium salt (E15B)

10



- The title mixture of diastereoisomers (E15) was prepared  
 15 from the phosphonic acid mixture of isomers (E12) (36.9  
 mg, 0.0935 mmol), 2-methylthio-2-imidazoline hydroiodide  
 (45.6 mg and, after 3h, 13.9 mg) and sodium bicarbonate  
 (47 mg and, after 3h, 7.8 mg) by the general method of  
 Example 14.

20

Observed FAB  $(M+H)^+$  507.  $C_{19}H_{37}N_6O_5PNa_2$  requires 506.


SUBSTITUTE SHEET

- 78 -

Example 16

N<sup>α</sup>-[N-((R)-1-Phosphonoethyl)-(S)-leucyl]-(S)-lysine  
methylamide (E16A) and N<sup>α</sup>-[N-((S)-1-phosphonoethyl)-(S)-  
 5 leucyl]-(S)-lysine methylamide (E16B)

10



The dibenzyl ester (D43) (1.0.g, 0.0014 mol) was  
 hydrogenated at atmospheric pressure by the method of  
 15 Example 1 to give the title compound mixture (E16) in  
 quantitative yield as a white crystalline solid.

Observed FAB (M+H)<sup>+</sup> 381. C<sub>15</sub>H<sub>33</sub>N<sub>4</sub>O<sub>5</sub>P requires M 380.

SUBSTITUTE SHEET



- 79 -

COLLAGENASE INHIBITOR ASSAY

The test is performed essentially as in Cawston and Barrett, Anal. Biochem. 99, 340-345 (1979). Compounds  
5 for testing are dissolved in methanol by sonication and added to collagenase (purified from culture supernatants from the human lung fibroblast cell line, WI-38) in buffer. After a 5 min pre-incubation at 37°C, the assay  
10 tubes are cooled to 4°C and <sup>3</sup>H-acetylated rat skin type I collagen is added. The assay tubes are incubated at 37°C overnight. The <sup>3</sup>H-collagen forms insoluble fibrils, which are the substrate for the enzyme.

To terminate the assay, the assay tubes are spun at 12000  
15 rpm for 15 minutes. Undigested <sup>3</sup>H-collagen is pelleted, while digested <sup>3</sup>H-collagen is found as soluble peptides in the supernatant. A sample of the supernatant is taken for liquid scintillation counting.

20 The activity of collagenase inhibitors (IC<sub>50</sub>: 50% inhibitory concentration) is expressed as that concentration of compound that inhibits a known (standard) concentration of enzyme by 50%.


25 The compounds of Examples E1-E9 had IC<sub>50</sub> values between  $1.8 \times 10^{-7}$  and  $2.2 \times 10^{-5}$ M.

SUBSTITUTE SHEET

- 80 -

Claims:


1. A compound of the formula (I) or a pharmaceutically  
5 acceptable salt, solvate or hydrate thereof:



- 15 in which,  
R is hydrogen, C<sub>1-6</sub> alkyl or optionally substituted  
benzyl;  
R<sub>1</sub> is hydrogen or C<sub>1-6</sub> alkyl;  
R<sub>2</sub> is C<sub>3-6</sub> alkyl;  
20 R<sub>3</sub> is -(CH<sub>2</sub>)<sub>n</sub>NR<sub>5</sub>R<sub>6</sub>, -(CH<sub>2</sub>)<sub>n</sub>NHCOR<sub>7</sub>, -(CH<sub>2</sub>)<sub>n</sub>CONH(CH<sub>2</sub>)<sub>q</sub>NR<sub>5</sub>R<sub>6</sub>,  
-(CH<sub>2</sub>)<sub>n</sub>NR<sub>8</sub>C(=NR<sub>9</sub>)NR<sub>5</sub>R<sub>6</sub> or -(CH<sub>2</sub>)<sub>n</sub>-R<sub>10</sub> where n is an  
integer from 1 to 6 and each of R<sub>5</sub> and R<sub>6</sub> is independently  
hydrogen or alkyl, or R<sub>5</sub> and R<sub>6</sub> together with the nitrogen  
atom to which they are bonded form a 5-, 6- or 7-membered  
25 ring with an optional oxygen or sulphur atom or an  
optionally substituted second nitrogen atom in the ring,  
R<sub>7</sub> is alkyl or -(CH<sub>2</sub>)<sub>n</sub>NR<sub>5</sub>R<sub>6</sub>, R<sub>8</sub> is hydrogen or alkyl, R<sub>9</sub>  
is hydrogen or alkyl or R<sub>9</sub> and R<sub>5</sub> together with the  
nitrogen atoms to which they are bonded form an optionally  
30 substituted 5-, 6- or 7-membered ring, and R<sub>10</sub> is an  
optionally substituted piperidyl ring;  
m is 1 or 2, and q is 2 to 4; and  
R<sub>4</sub> is hydrogen, alkyl, and -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>OR<sub>11</sub> or  
-CH<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>OCOR<sub>12</sub> or

SUBSTITUTE SHEET

- 81 -



- 5 where  $n$  is an integer from 1 to 6;  $R_{11}$ ,  $R_{12}$  and  $R_{13}$  are hydrogen or  $C_{1-6}$ alkyl; and  $R_{14}$  is hydroxy or  $-O-C_{1-6}$ alkyl or  $-NR_5R_6$  (where  $R_5$  and  $R_6$  may be linked to form a heterocyclic ring).
- 10 2. A compound according to claim 1 in which  $R$  is hydrogen, methyl or ethyl.
3. A compound according to either of claims 1 or 2 in which  $R_1$  is hydrogen, methyl, ethyl, isopropyl or  $n$ -butyl.
- 15 4. A compound according to any one of claims 1 to 3 in which  $R_2$  is  $n$ -butyl, iso-butyl or sec-butyl.
5. A compound according to any one of claims 1 to 4 in which  $R_3$  is  $-(CH_2)_nNR_5R_6$  where  $R_5$  and  $R_6$  are hydrogen or methyl,  $-(CH_2)_nNHCOR_7$  where  $R_7$  is  $-(CH_2)_mNR_5R_6$  in which  $m$  is 1 and  $R_5$  and  $R_6$  are hydrogen,  $-(CH_2)_nCONH(CH_2)_qNR_5R_6$  where  $q$  is 2 and  $R_5$  and  $R_6$  together with the nitrogen atom to which they are bonded form a 5-, 6- or 7-membered ring,
- 20  $-(CH_2)_nNR_8C(=NR_9)NR_5R_6$  where  $R_5$ ,  $R_6$ ,  $R_8$  and  $R_9$  are all hydrogen,  $-(CH_2)_nNR_8C(=NR_9)NR_5R_6$  where  $R_5$  and  $R_9$  together with the nitrogen atoms to which they are bonded form an optionally substituted 2-imidazoliny group,  $-(CH_2)_nR_{10}$  where  $R_{10}$  is optionally substituted piperidyl, and  $n$  is an
- 25 integer from 1 to 4.
- 30 6. A compound according to any one of claims 1 to 5 in which  $R_4$  is methyl, ethyl,  $-(CH_2)_2OCH_3$ ,  $-CH(CH_3)CO_2CH_3$  and  $-(CH_2)_2OH$ .

35

- 82 -

7. A compound according to any one of claims 1 to 6 in which R is hydrogen, R<sub>1</sub> is methyl or ethyl, R<sub>2</sub> is iso-butyl, R<sub>3</sub> is -(CH<sub>2</sub>)<sub>n</sub>NR<sub>5</sub>R<sub>6</sub> where n is 3 or 4 and R<sub>5</sub> and R<sub>6</sub> are both hydrogen or methyl, -(CH<sub>2</sub>)<sub>4</sub>NHCOR<sub>7</sub> where R<sub>7</sub> is
- 5 -CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>CONH(CH<sub>2</sub>)<sub>2</sub>NR<sub>5</sub>R<sub>6</sub> where R<sub>5</sub> and R<sub>6</sub> are joined together to form a pyrrolidine ring,
- (CH<sub>2</sub>)<sub>n</sub>NR<sub>8</sub>C(=NR<sub>9</sub>)NR<sub>5</sub>R<sub>6</sub> where n is 3 or 4 and R<sub>5</sub>, R<sub>6</sub>, R<sub>8</sub> and R<sub>9</sub> are all hydrogen, -(CH<sub>2</sub>)<sub>4</sub>NR<sub>8</sub>C(=NR<sub>9</sub>)NR<sub>5</sub>R<sub>6</sub> where R<sub>5</sub> and R<sub>9</sub> together with the nitrogen atoms to which they are
- 10 bonded form an optionally substituted 2-imidazoliny group and R<sub>6</sub> and R<sub>8</sub> are both hydrogen, -(CH<sub>2</sub>)<sub>n</sub>NHC(=NH)NH<sub>2</sub> where n is 3 or 4, and -CH<sub>2</sub>R<sub>10</sub> where R<sub>10</sub> is 4-piperidyl; and R<sub>4</sub> is methyl or -(CH<sub>2</sub>)<sub>2</sub>OH.
- 15 8. A compound according to any one of claims 1 to 7 in which the chiral centre marked with an asterisk in formula (I) has the S-configuration.
9. A compound according to claim 1 which is
- 20 N<sup>α</sup>-[N-((R)-1-phosphonopropyl)-(S)-leucyl]-(S)-lysine methylamide;
- N<sup>α</sup>-[N-((R)-1-phosphonopropyl)-(S)-leucyl]-N<sup>ε</sup>-glycyl-(S)-lysine methylamide;
- N-[N-((R)-1-phosphonopropyl)-(S)-leucyl]-β-[2-
- 25 pyrrolidinoethyl)amide]-(S)-aspartic acid methylamide;
- N<sup>α</sup>-[N-((R)-1-phosphonopropyl)-(S)-leucyl]-(S)-arginine methylamide;
- N<sup>α</sup>-[N-((R)-1-phosphonopropyl)-(S)-leucyl]-(R)-β-(4-
- piperidyl)alanine methylamide;
- 30 N<sup>α</sup>-[N-((R)-1-phosphonopropyl)-(S)-leucyl]-(S)-β-(4-
- piperidyl)alanine methylamide;
- N<sup>α</sup>-[N-((R)-1-phosphonopropyl)-(S)-leucyl]-(S)-ornithine methylamide;

SUBSTITUTE SHEET


- 83 -

- $N^{\alpha}$ -[N-((R)-1-phosphonopropyl)-(S)-leucyl]- $N^{\epsilon}$ -dimethyl-(S)-lysine methylamide;
- $N^{\alpha}$ -[N-((R)-1-phosphonopropyl)-(S)-leucyl]- $N^{\epsilon}$ -dimethyl-(S)-ornithine methylamide;
- 5  $N^{\alpha}$ -[N-((S)-1-phosphonopropyl)-(S)-leucyl]-(S)-lysine methylamide, hydrobromide salt;
- $N^{\alpha}$ -[N-((R)-1-phosphonopropyl)-(S)-leucyl]-(S)-lysine 2-hydroxyethylamide;
- $N^{\alpha}$ -[N-((S)-1-phosphonopropyl)-(S)-leucyl]-(S)-lysine 2-hydroxyethylamide;
- 10  $N^{\alpha}$ -[N-((R)-1-phosphonopropyl)-(S)-leucyl]-(S)-lysine methylamide;
- $N^{\alpha}$ -[N-((S)-1-phosphonopropyl)-(S)-leucyl]-(S)-lysine methylamide;
- 15  $N^{\alpha}$ -[N-((S)-1-phosphonopropyl)-(S)-leucyl]-(S)-arginine methylamide;
- $N^{\alpha}$ -[N-((R)-1-phosphonopropyl)-(S)-leucyl]-(S)-homoarginine methylamide, disodium salt;
- $N^{\alpha}$ -[N-((S)-1-phosphonopropyl)-(S)-leucyl]-(S)-homoarginine methylamide, disodium salt;
- 20  $N^{\alpha}$ -[N-((R)-1-phosphonopropyl)-(S)-leucyl]-(S)- $N^{\epsilon}$ -(2-imidazoliny)-lysine methylamide, disodium salt;
- $N^{\alpha}$ -[N-((S)-1-phosphonopropyl)-(S)-leucyl]-(S)- $N^{\epsilon}$ -(2-imidazoliny)-lysine methylamide, disodium salt;
- 25  $N^{\alpha}$ -[N-((R)-1-phosphonoethyl)-(S)-leucyl]-(S)-lysine methylamide;
- $N^{\alpha}$ -[N-((S)-1-phosphonoethyl)-(S)-leucyl]-(S)-lysine methylamide.
- 30 10. A process for the preparation of a compound as claimed in claim 1 which process comprises converting a group  $R_{20}$  to hydrogen by cleaving a group  $R_{20}$  from a compound of formula (II):

SUBSTITUTE SHEET

- 84 -

5



wherein  $R_{20}$  is alkyl, optionally substituted phenyl, or  
 10 optionally substituted benzyl and  $R_{21}$  is hydrogen, alkyl,  
 optionally substituted phenyl, or optionally substituted  
 benzyl and  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  are as defined in formula  
 (I), and where necessary, converting  $R_{21}$  to hydrogen, and  
 15 (I) to a further compound of formula (I).

11. A compound of the formula (II) as defined in claim 10  
 subject to the proviso that  $R_{21}$  is not hydrogen.

20 12. A compound according to claim 11 which is  
 $N^\alpha$ -[N-((R)-1-dibenzyloxyphosphinylpropyl)-(S)-leucyl]- $N^\epsilon$ -  
 benzyloxycarbonyl-(S)-lysine methylamide;  
 $N^\alpha$ -[N-((R)-1-phosphonopropyl)-(S)-leucyl]- $N^\epsilon$ -(N-benzyl-  
 oxycarbonylglycyl)-(S)-lysine methylamide, dibenzyl ester;  
 25 N-[N-((R)-1-dibenzyloxyphosphinylpropyl)-(S)-leucyl]- $\beta$ -  
 [(2-pyrrolidinoethyl)amide]-(S)-aspartic acid methylamide;  
 $N^\alpha$ -[N-((R)-1-dibenzyloxyphosphinylpropyl)-(S)-leucyl]- $N^\omega$ -  
 nitro-(S)-arginine methylamide;  
 $N^\alpha$ -[N-((R)-1-dibenzyloxyphosphinylpropyl)-(S)-leucyl]-(R)-  
 30  $\beta$ -(4-(N-benzyloxycarbonyl)piperidyl)alanine methylamide;

SUBSTITUTE SHEET

- 85 -

- $N^{\alpha}$ -[N-((R)-1-dibenzyloxyphosphinylpropyl)-(S)-leucyl]-(S)-  
 $\beta$ -(4-(N-benzyloxycarbonyl)piperidyl)alanine methylamide;  
 $N^{\alpha}$ -[N-((R)-1-dibenzyloxyphosphinylpropyl)-(S)-leucyl]- $N^{\epsilon}$ -  
 benzyloxycarbonyl-(S)-ornithine methylamide;  
 5  $N^{\alpha}$ -[N-((R)-1-dibenzyloxyphosphinylpropyl)-(S)-leucyl]- $N^{\epsilon}$ -  
 dimethyl-(S)-lysine methylamide;  
 $N^{\alpha}$ -[N-((R)-1-dibenzyloxyphosphinylpropyl)-(S)-leucyl]- $N^{\epsilon}$ -  
 dimethyl-(S)-ornithine methylamide;  
 $N^{\alpha}$ -[N-((S)-1-diethoxyphosphinylpropyl)-(S)-leucyl]-(S)-  
 10 lysine methylamide;  
 $N^{\alpha}$ -[N-((R)-1-dibenzyloxyphosphinylpropyl)-(S)-leucyl]-(S)-  
 $N^{\epsilon}$ -benzyloxycarbonyl-lysine 2-hydroxyethylamide;  
 $N^{\alpha}$ -[N-((S)-1-dibenzyloxyphosphinylpropyl)-(S)-leucyl]-(S)-  
 $N^{\epsilon}$ -benzyloxycarbonyl-lysine 2-hydroxyethylamide;  
 15  $N^{\alpha}$ -[N-((S)-1-dibenzyloxyphosphinylpropyl)-(S)-leucyl]-(S)-  
 $N^{\epsilon}$ -benzyloxycarbonyl-lysine methylamide;  
 $N^{\alpha}$ -[N-((S)-1-dibenzyloxyphosphinylpropyl)-(S)-leucyl]- $N^{\omega}$ -  
 nitro-(S)-arginine methylamide;  
 $N^{\alpha}$ -[N-((R)-1-dibenzyloxyphosphinylethyl)-(S)-leucyl]-(S)-  
 20  $N^{\epsilon}$ -benzyloxycarbonyl-lysine methylamide; and  
 $N^{\alpha}$ -[N-((S)-1-dibenzyloxyphosphinylethyl)-(S)-leucyl]-(S)-  
 $N^{\epsilon}$ -benzyloxycarbonyl-lysine methylamide.

13. A pharmaceutical composition comprising a compound  
 25 according to any one of claims 1 to 9 or a  
 pharmaceutically acceptable salt, solvate or hydrate  
 thereof, and a pharmaceutically acceptable carrier.

14. A compound according to any one of claims 1 to 9 or a  
 30 pharmaceutically acceptable salt, solvate or hydrate  
 thereof, for use as an active therapeutic substance.

- 86 -

15. A compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt, solvate or hydrate thereof, for use in the treatment of conditions in which degradation of connective tissue and other proteinaceous components of the body occurs.

16. The use of a compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt, solvate or hydrate thereof, in the manufacture of a medicament for the treatment of conditions in which degradation of connective tissue and other proteinaceous components of the body occurs.



# INTERNATIONAL SEARCH REPORT

International Application No PCT/GB 91/00538

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>8</sup> According to International Patent Classification (IPC) or to both National Classification and IPC IPC <sup>5</sup> : C 07 K 5/06, C 07 K 5/08, A 61 K 37/64, C 07 K 5/02														
<b>II. FIELDS SEARCHED</b> <div style="text-align: center;">Minimum Documentation Searched <sup>7</sup></div> <table style="width: 100%; border: none;"> <tr> <td style="width: 30%; border: none;">Classification System</td> <td style="border: none;">Classification Symbols</td> </tr> <tr> <td style="border: none;">IPC<sup>5</sup></td> <td style="border: none;">C 07 K, A 61 K</td> </tr> </table> <div style="text-align: center; padding-top: 10px;">Documentation Searched other than Minimum Documentation to the extent that such Documents are Included in the Fields Searched <sup>8</sup></div>			Classification System	Classification Symbols	IPC <sup>5</sup>	C 07 K, A 61 K								
Classification System	Classification Symbols													
IPC <sup>5</sup>	C 07 K, A 61 K													
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%; padding: 5px;">Category <sup>9</sup></th> <th style="width: 60%; padding: 5px;">Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup></th> <th style="width: 30%; padding: 5px;">Relevant to Claim No. <sup>13</sup></th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">           EP, A, 0320118 (BEECHAM GROUP PLC.)            14 June 1989            see page 3, line 42 - page 8, line 41;            description 13, example 5; claims 1-16            cited in the application            ---         </td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-16</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">           Journal of Medical Chemistry, volume 33,            1990, American Chemical Society (US),            Z.P. Kortylewicz et al.: "Phosphora-            midate peptide inhibitors of human skin            fibroblast collagenase", pages 263-273            see the whole document            ---         </td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-16</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">           Biochemistry, volume 28, no.12, June 1989, American            Chemical Society, (Washington, DC, US),            D. Grobelny et al.: "Binding energetics            of phosphorus-containing inhibitors of            thermolysin", pages 4948-4951            see the whole document            -----         </td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-16</td> </tr> </tbody> </table>			Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>	X	EP, A, 0320118 (BEECHAM GROUP PLC.) 14 June 1989 see page 3, line 42 - page 8, line 41; description 13, example 5; claims 1-16 cited in the application ---	1-16	A	Journal of Medical Chemistry, volume 33, 1990, American Chemical Society (US), Z.P. Kortylewicz et al.: "Phosphora- midate peptide inhibitors of human skin fibroblast collagenase", pages 263-273 see the whole document ---	1-16	A	Biochemistry, volume 28, no.12, June 1989, American Chemical Society, (Washington, DC, US), D. Grobelny et al.: "Binding energetics of phosphorus-containing inhibitors of thermolysin", pages 4948-4951 see the whole document -----	1-16
Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>												
X	EP, A, 0320118 (BEECHAM GROUP PLC.) 14 June 1989 see page 3, line 42 - page 8, line 41; description 13, example 5; claims 1-16 cited in the application ---	1-16												
A	Journal of Medical Chemistry, volume 33, 1990, American Chemical Society (US), Z.P. Kortylewicz et al.: "Phosphora- midate peptide inhibitors of human skin fibroblast collagenase", pages 263-273 see the whole document ---	1-16												
A	Biochemistry, volume 28, no.12, June 1989, American Chemical Society, (Washington, DC, US), D. Grobelny et al.: "Binding energetics of phosphorus-containing inhibitors of thermolysin", pages 4948-4951 see the whole document -----	1-16												
<sup>10</sup> Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed		"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "A" document member of the same patent family												
<b>IV. CERTIFICATION</b> <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; vertical-align: top;">           Date of the Actual Completion of the International Search   <div style="text-align: center;">28th June 1991</div>           International Searching Authority   <div style="text-align: center;">EUROPEAN PATENT OFFICE</div> </td> <td style="width: 50%; border: none; vertical-align: top;">           Date of Mailing of this International Search Report   <div style="text-align: center;">06.08.91</div>           Signature of Authorized Officer   <div style="text-align: center;">miss T. MORTENSEN </div> </td> </tr> </table>			Date of the Actual Completion of the International Search  <div style="text-align: center;">28th June 1991</div> International Searching Authority  <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Date of Mailing of this International Search Report  <div style="text-align: center;">06.08.91</div> Signature of Authorized Officer  <div style="text-align: center;">miss T. MORTENSEN </div>										
Date of the Actual Completion of the International Search  <div style="text-align: center;">28th June 1991</div> International Searching Authority  <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Date of Mailing of this International Search Report  <div style="text-align: center;">06.08.91</div> Signature of Authorized Officer  <div style="text-align: center;">miss T. MORTENSEN </div>													

ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.

GB 9100538

SA 46372

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office EDP file on 30/07/91  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0320118	14-06-89	AU-A- 2507088	25-05-89
		JP-A- 1160992	23-06-89
		US-A- 4935404	19-06-90
-----			

EPO FORM P0479

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82